dalteparin has been researched along with Myocardial Infarction in 391 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this French cohort of NSTEMI patients, predominantly managed invasively, there was no evidence that fondaparinux was superior to enoxaparin as regards bleeding events or 1-year mortality (FAST-MI 2010; NCT01237418)." | 9.20 | Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. ( Bonnefoy-Cudraz, E; Collet, JP; Coste, P; Danchin, N; Ennezat, PV; Puymirat, E; Richard, P; Roul, G; Schiele, F; Simon, T, 2015) |
| "Compared with a heparin-based strategy, fondaparinux reduced mortality, ischemic events, and major bleeding across the full spectrum of acute coronary syndromes and was associated with a more favorable net clinical outcome in patients undergoing either an invasive or a conservative management strategy." | 9.13 | Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass ( Afzal, R; Avezum, A; Bassand, JP; Boden, WE; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Flather, M; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Piegas, LS; Rupprecht, HJ; Steg, PG; Widimsky, P; Yusuf, S, 2008) |
| "Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin." | 9.12 | Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006) |
| "Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers." | 9.12 | Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006) |
| "The purpose of this study was to determine the efficacy and safety of enoxaparin (ENOX) versus unfractionated heparin (UFH) in patients with ST-segment elevation myocardial infarction (STEMI) receiving fibrinolytic therapy with and without clopidogrel." | 9.12 | Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. ( Antman, EM; Braunwald, E; Dalby, A; Duris, T; Gao, R; Lopez-Sendon, J; Morrow, DA; Murphy, SA; Pfisterer, M; Sabatine, MS, 2007) |
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 9.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| "The OASIS-5 trial was a double-blind, randomized comparison of fondaparinux and enoxaparin in 20,078 patients with acute coronary syndrome." | 9.12 | Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Fox, KA; Granger, CB; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2007) |
| "The present study hypothesis was that eptifibatide offered further antiplatelet efficacy above clopidogrel in non-ST-elevation myocardial infarction (NSTEMI) patients before an expeditive coronary intervention." | 9.11 | Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel ( Bal dit Sollier, C; Choussat, R; Collet, JP; Dalby, M; Drobinski, G; Drouet, L; Gallois, V; Montalescot, G; Soulat, T; Thomas, D; Vicaut, E, 2004) |
| "Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared." | 9.11 | [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005) |
| "The low-molecular-weight heparins (LMWHs) enoxaparin and dalteparin have shown superior and equivalent efficacy, respectively, over unfractionated heparin (UFH) in patients with unstable angina pectoris (UAP) or non-ST-segment elevation myocardial infarction (NSTEMI)." | 9.10 | Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). ( Bal-dit-Sollier, C; Chibedi, D; Choussat, R; Cohen, A; Collet, JP; Dalby, M; Drouet, L; Dubois-Randé, JL; Guermonprez, JL; Metzger, JP; Montalescot, G; Slama, M; Soulat, T; Steg, PG; Tarragano, F, 2003) |
| "The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion." | 9.10 | The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial ( Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD, 2003) |
| "The FRISC II trial demonstrated that, for patients with unstable coronary artery disease, an early invasive strategy following acute treatment with dalteparin and aspirin, was superior to a more conservative approach." | 9.10 | Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. ( Husted, SE; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2002) |
| "Overall there were higher thrombolysis in myocardial infarction (TIMI) flows in the infarct related coronary artery in the dalteparin group (p=0." | 9.10 | Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. ( Bergstrand, L; Dellborg, M; Fellenius, C; Granger, CB; Lindahl, B; Lins, LE; Nilsson, T; Pehrsson, K; Siegbahn, A; Swahn, E; Wallentin, L, 2003) |
| "Tirofiban, an intravenous glycoprotein IIb/IIIa antagonist, and enoxaparin, a low molecular weight heparin, have each been shown to be effective at reducing cardiac ischemic events compared to unfractionated heparin alone in separate trials of patients with unstable angina and non-Q-wave myocardial infarction." | 9.09 | Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. ( Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD, 1999) |
| "The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial." | 9.09 | Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001) |
| "This randomized, double blind, placebo-controlled pilot trial evaluated the effect of dalteparin as an adjuvant to thrombolysis in patients with acute myocardial infarction regarding early reperfusion, recurrent ischemia and patency at 24 h." | 9.09 | Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). ( Ahlberg, G; Frostfeldt, G; Gustafsson, G; Helmius, G; Lindahl, B; Nygren, A; Siegbahn, A; Swahn, E; Venge, P; Wallentin, L, 1999) |
| "Fibrin monomer was measured in plasma samples from 293 patients enrolled in a randomized clinical trial of low molecular weight heparin (dalteparin) in acute myocardial infarction (the FRAMI trial)." | 9.09 | Fibrin monomer antigen: a novel marker of mortality in acute myocardial infarction. ( Abildgaard, U; Dempfle, CE; Kontny, F, 1999) |
| "The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI)." | 9.08 | Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. ( Abildgaard, U; Dale, J; Kontny, F; Pedersen, TR, 1997) |
| "We sought explore the relative benefits of unfractionated heparin (UFH) compared with enoxaparin, alone or in combination with clopidogrel, in ST-segment elevation myocardial infarction (STEMI) patients not undergoing reperfusion therapy." | 7.81 | Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy. ( Badimon, L; Bugiardini, R; Calmac, L; Cenko, E; Daullxhiu, I; Dorobantu, M; Kedev, S; Knežević, B; Koller, A; Manfrini, O; Miličić, D; Puddu, PE; Ricci, B; Trninic, D; Vasiljevic, Z, 2015) |
| " We here present a 76-year-old man with renal insufficiency treated with dalteparin for acute myocardial infarction, who developed catastrophic SRH with intra-abdominal hypertension (IAH) and hemothorax." | 7.78 | Dalteparin-associated catastrophic retroperitoneal hematoma successfully treated with recombinant factor VIIa. ( Chen, YC; Tsao, CW; Wang, CH; Yang, SS, 2012) |
| "We have determined the immediate effects of the main coronary reperfusion procedures on the plasma concentrations of myeloperoxidase (MPO), pregnancy-associated plasma protein A (PAPP-A), fibrin monomer (FM) and D-dimer (DD)." | 7.74 | The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction. ( Brügger-Andersen, T; Grundt, H; Hetland, Ø; Nilsen, DW; Pönitz, V, 2007) |
| "The purpose of this study was to determine the clinical outcomes of abciximab combined with the low molecular weight heparin (LMWH), dalteparin, in high-risk percutaneous coronary intervention (PCI) patients with acute myocardial infarction (AMI)." | 7.73 | Comparison of abciximab combined with dalteparin or unfractionated heparin in high-risk percutaneous coronary intervention in acute myocardial infarction patients. ( Ahn, YK; Cho, JG; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, KH; Kim, W; Park, JC, 2006) |
| "Dalteparin was effective and safe in primary PCI of STEMI patients and combined dalteparin with tirofiban was effective and safe without significant bleeding complications compared with UFH." | 6.76 | Comparison of tirofiban combined with dalteparin or unfractionated heparin in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction patients. ( Ge, YG; Li, WM; Ni, ZH; Wang, HS; Wang, LF; Xu, L; Yang, XC; Zhang, DP, 2011) |
| "Fibrin formation was decreased by Parnaparin in a concentration-dependent way, according to both the anti-Xa activity and the APTT ratio." | 6.67 | Effects of two dosages of subcutaneous low molecular weight heparin (Parnaparin) and of unfractionated heparin on fibrin formation and lipolysis in acute myocardial infarction. ( Branzi, A; Cervi, V; Magnani, B; Melandri, G; Semprini, F, 1992) |
| "Fondaparinux was compared with enoxaparin or usual care, depending on the setting." | 6.44 | Efficacy and safety of fondaparinux in patients with acute coronary syndromes. ( Bassand, JP; Cadroy, Y; Richard-Lordereau, I, 2007) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 5.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| "In this French cohort of NSTEMI patients, predominantly managed invasively, there was no evidence that fondaparinux was superior to enoxaparin as regards bleeding events or 1-year mortality (FAST-MI 2010; NCT01237418)." | 5.20 | Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. ( Bonnefoy-Cudraz, E; Collet, JP; Coste, P; Danchin, N; Ennezat, PV; Puymirat, E; Richard, P; Roul, G; Schiele, F; Simon, T, 2015) |
| " We examined the incidence and outcomes after bleeding in 20 078 patients with acute coronary syndromes (ACS) enrolled in the OASIS-5 trial who were treated with fondaparinux or the low-molecular weight heparin, enoxaparin." | 5.14 | Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Fox, KA; Granger, CB; Joyner, CD; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2009) |
| "Enoxaparin was superior to unfractionated heparin (UFH), regardless of fibrinolytic agent in ST-elevation myocardial infarction (STEMI) patients receiving fibrinolytic therapy in ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction 25) trial." | 5.14 | Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. ( Antman, EM; Giraldez, RR; Giugliano, RP; Mohanavelu, S; Morrow, DA; Nicolau, JC; Wiviott, SD, 2009) |
| "Compared with a heparin-based strategy, fondaparinux reduced mortality, ischemic events, and major bleeding across the full spectrum of acute coronary syndromes and was associated with a more favorable net clinical outcome in patients undergoing either an invasive or a conservative management strategy." | 5.13 | Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass ( Afzal, R; Avezum, A; Bassand, JP; Boden, WE; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Flather, M; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Piegas, LS; Rupprecht, HJ; Steg, PG; Widimsky, P; Yusuf, S, 2008) |
| "Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin." | 5.12 | Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006) |
| "Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity." | 5.12 | Comparison of fondaparinux and enoxaparin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Fox, KA; Granger, CB; Joyner, C; Mehta, SR; Peters, RJ; Pogue, J; Wallentin, L; Yusuf, S, 2006) |
| "The goal of this study was to evaluate glycoprotein IIb/IIIa inhibition with eptifibatide when administered with indirect thrombin inhibition as compared with monotherapy with direct thrombin inhibition with bivalirudin among patients with non-ST-segment elevation acute coronary syndromes (ACS)." | 5.12 | A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. ( Braunwald, E; Bulle, T; Cohen, DJ; Fish, P; Gibson, CM; Jennings, LK; Kovach, R; Lakkis, N; Lui, HH; McCabe, CH; Morrow, DA; Murphy, SA; Palabrica, TM; Stone, PH, 2006) |
| "Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers." | 5.12 | Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006) |
| "The purpose of this study was to determine the efficacy and safety of enoxaparin (ENOX) versus unfractionated heparin (UFH) in patients with ST-segment elevation myocardial infarction (STEMI) receiving fibrinolytic therapy with and without clopidogrel." | 5.12 | Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. ( Antman, EM; Braunwald, E; Dalby, A; Duris, T; Gao, R; Lopez-Sendon, J; Morrow, DA; Murphy, SA; Pfisterer, M; Sabatine, MS, 2007) |
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 5.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| "The OASIS-5 trial was a double-blind, randomized comparison of fondaparinux and enoxaparin in 20,078 patients with acute coronary syndrome." | 5.12 | Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Fox, KA; Granger, CB; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2007) |
| "The present study hypothesis was that eptifibatide offered further antiplatelet efficacy above clopidogrel in non-ST-elevation myocardial infarction (NSTEMI) patients before an expeditive coronary intervention." | 5.11 | Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel ( Bal dit Sollier, C; Choussat, R; Collet, JP; Dalby, M; Drobinski, G; Drouet, L; Gallois, V; Montalescot, G; Soulat, T; Thomas, D; Vicaut, E, 2004) |
| "The OASIS-5 trial is a randomized, double-blind trial of fondaparinux versus enoxaparin in 20,000 patients with unstable angina or non-ST-segment elevation myocardial infarction." | 5.11 | Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. ( Bassand, JP; Budaj, A; Chrolavicius, S; Fox, KA; Granger, CB; Joyner, C; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2005) |
| "Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared." | 5.11 | [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005) |
| "The low-molecular-weight heparins (LMWHs) enoxaparin and dalteparin have shown superior and equivalent efficacy, respectively, over unfractionated heparin (UFH) in patients with unstable angina pectoris (UAP) or non-ST-segment elevation myocardial infarction (NSTEMI)." | 5.10 | Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). ( Bal-dit-Sollier, C; Chibedi, D; Choussat, R; Cohen, A; Collet, JP; Dalby, M; Drouet, L; Dubois-Randé, JL; Guermonprez, JL; Metzger, JP; Montalescot, G; Slama, M; Soulat, T; Steg, PG; Tarragano, F, 2003) |
| "The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion." | 5.10 | The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial ( Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD, 2003) |
| "The FRISC II trial demonstrated that, for patients with unstable coronary artery disease, an early invasive strategy following acute treatment with dalteparin and aspirin, was superior to a more conservative approach." | 5.10 | Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. ( Husted, SE; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2002) |
| "Overall there were higher thrombolysis in myocardial infarction (TIMI) flows in the infarct related coronary artery in the dalteparin group (p=0." | 5.10 | Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. ( Bergstrand, L; Dellborg, M; Fellenius, C; Granger, CB; Lindahl, B; Lins, LE; Nilsson, T; Pehrsson, K; Siegbahn, A; Swahn, E; Wallentin, L, 2003) |
| "In patients receiving intracoronary stents, stent thrombosis is reduced when ticlopidine therapy is combined with aspirin after the procedure." | 5.09 | Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. ( Bell, MR; Berger, PB; Grill, DE; Hasdai, D; Holmes, DR; Melby, S, 1999) |
| "Tirofiban, an intravenous glycoprotein IIb/IIIa antagonist, and enoxaparin, a low molecular weight heparin, have each been shown to be effective at reducing cardiac ischemic events compared to unfractionated heparin alone in separate trials of patients with unstable angina and non-Q-wave myocardial infarction." | 5.09 | Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. ( Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD, 1999) |
| "Enoxaparin, a low-molecular-weight heparin, and tirofiban, an intravenous platelet glycoprotein IIb/IIIa receptor antagonist, have each been shown to be effective in reducing cardiac ischemic events compared to unfractionated heparin alone in separate trials of patients with unstable angina and non-Q wave myocardial infarction." | 5.09 | Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes. ( Cohen, M, 2000) |
| "The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial." | 5.09 | Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001) |
| "This randomized, double blind, placebo-controlled pilot trial evaluated the effect of dalteparin as an adjuvant to thrombolysis in patients with acute myocardial infarction regarding early reperfusion, recurrent ischemia and patency at 24 h." | 5.09 | Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). ( Ahlberg, G; Frostfeldt, G; Gustafsson, G; Helmius, G; Lindahl, B; Nygren, A; Siegbahn, A; Swahn, E; Venge, P; Wallentin, L, 1999) |
| "Fibrin monomer was measured in plasma samples from 293 patients enrolled in a randomized clinical trial of low molecular weight heparin (dalteparin) in acute myocardial infarction (the FRAMI trial)." | 5.09 | Fibrin monomer antigen: a novel marker of mortality in acute myocardial infarction. ( Abildgaard, U; Dempfle, CE; Kontny, F, 1999) |
| "Long-term dalteparin lowers the risk of death, myocardial infarction, and revascularisation in unstable coronary-artery disease at least during the first month of therapy." | 5.09 | Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. ( , 1999) |
| "The FRISC II study addressed two key questions in the management of acute coronary syndromes: is it beneficial to extend low-molecular-weight heparin (LMWH) therapy with dalteparin beyond the initial period of acute treatment; and, is a strategy of early invasive therapy, including angioplasty and surgical revascularization, preferable to a more conservative strategy? The study focused on patients with unstable coronary artery disease (UCAD), that is, angina and non-ST-segment-elevation myocardial infarction (MI)." | 5.09 | Improving outcomes in acute coronary syndromes--the FRISC II trial. ( Kontny, F, 2001) |
| "Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase." | 5.08 | A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. ( Bigonzi, F; Califf, RM; Cohen, M; Demers, C; Fox, KA; Fromell, GJ; Goodman, S; Gurfinkel, EP; Langer, A; Premmereur, J; Turpie, AG, 1997) |
| "1506 patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) took part in a double-blind trial and were randomly assigned subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days) or placebo injections." | 5.08 | Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. ( , 1996) |
| "Our results add to previous evidence suggesting that the low-molecular-weight heparin dalteparin administered by twice-daily subcutaneous injection may be an alternative to unfractionated heparin in the acute treatment of unstable angina or non-Q-wave myocardial infarction." | 5.08 | Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) ( Buchwald, A; Hillis, SE; Klein, W; Ludwig, K; Monrad, S; Olaisson, E; Sanz, G; Turpie, AG; Undeland, S; van der Meer, J, 1997) |
| "The safety and efficacy of weight-adjusted, low-molecular-weight heparin (dalteparin) was compared with that of unfractionated heparin during 6 days of treatment in 1,482 patients with unstable angina or non-Q-wave myocardial infarction." | 5.08 | Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease. ( Buchwald, A; Hillis, WS; Klein, W; Ludwig, K; Monrad, S; Olaisson, E; Sanz, G; Turpie, AG; Undeland, S; van der Meer, J, 1997) |
| "The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI)." | 5.08 | Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. ( Abildgaard, U; Dale, J; Kontny, F; Pedersen, TR, 1997) |
| "Dabigatran 150 mg twice daily was shown to be superior to warfarin in preventing stroke in subjects with nonvalvular atrial fibrillation (SPAF) in the RE-LY (Randomized Evaluation of Long-term anticoagulation therapY) trial." | 4.89 | Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. ( Clemens, A; Fraessdorf, M; Friedman, J, 2013) |
| "On the basis of this methodology, enoxaparin would appear to be more effective than placebo when added to aspirin in acute coronary syndromes." | 4.81 | Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control. ( Cruickshank, MK; Massel, D, 2002) |
| "Antithrombotic and antiplatelet agents, particularly unfractionated heparin and aspirin, are longstanding therapeutic mainstays for acute coronary syndromes such as unstable angina and non-Q-wave myocardial infarction (MI)." | 4.80 | Anticoagulants in acute coronary syndromes. ( Turpie, AG, 1999) |
| "The current article describes a 72-year-old woman who suffered an acute myocardial infarction due to plaque erosion (PE) 2 weeks after abemaciclib treatment onset due to advanced breast cancer." | 4.02 | Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect? ( Alfonso, F; Alvarado-Casas, T; Rivero, F; Salamanca, J; Vera, A, 2021) |
| "We sought explore the relative benefits of unfractionated heparin (UFH) compared with enoxaparin, alone or in combination with clopidogrel, in ST-segment elevation myocardial infarction (STEMI) patients not undergoing reperfusion therapy." | 3.81 | Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy. ( Badimon, L; Bugiardini, R; Calmac, L; Cenko, E; Daullxhiu, I; Dorobantu, M; Kedev, S; Knežević, B; Koller, A; Manfrini, O; Miličić, D; Puddu, PE; Ricci, B; Trninic, D; Vasiljevic, Z, 2015) |
| " In early trials, such as FRISC (Fragmin during instability in coronary artery disease) and FRIC (Fragmin in unstable coronary artery disease), the results of extended treatment were inconclusive; however, the trial populations included patients of relatively low risk and used a once-daily dosing regimen." | 3.79 | Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease. ( Husted, S; Kher, A, 2000) |
| "Treatment with dalteparin reduced the risk of death and myocardial infarction in high-risk (i." | 3.79 | Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial. ( Wallentin, L, 2000) |
| " We here present a 76-year-old man with renal insufficiency treated with dalteparin for acute myocardial infarction, who developed catastrophic SRH with intra-abdominal hypertension (IAH) and hemothorax." | 3.78 | Dalteparin-associated catastrophic retroperitoneal hematoma successfully treated with recombinant factor VIIa. ( Chen, YC; Tsao, CW; Wang, CH; Yang, SS, 2012) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs) may be prothrombotic, may worsen hypertension or congestive heart failure and obstruct access to the binding site of aspirin to cyclooxygenase-1 and thereby interfere with aspirin's mechanism of action in reducing death and recurrent myocardial infarction (MI)." | 3.75 | Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. ( Antman, EM; Aylward, PE; Bergovec, M; Buros, JL; Col, JJ; Gibson, CM; Goodman, SG; Gulba, D; Kunadian, V; Murphy, SA; Pride, YB; Zorkun, C, 2009) |
| "We have determined the immediate effects of the main coronary reperfusion procedures on the plasma concentrations of myeloperoxidase (MPO), pregnancy-associated plasma protein A (PAPP-A), fibrin monomer (FM) and D-dimer (DD)." | 3.74 | The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction. ( Brügger-Andersen, T; Grundt, H; Hetland, Ø; Nilsen, DW; Pönitz, V, 2007) |
| "The purpose of this study was to determine the clinical outcomes of abciximab combined with the low molecular weight heparin (LMWH), dalteparin, in high-risk percutaneous coronary intervention (PCI) patients with acute myocardial infarction (AMI)." | 3.73 | Comparison of abciximab combined with dalteparin or unfractionated heparin in high-risk percutaneous coronary intervention in acute myocardial infarction patients. ( Ahn, YK; Cho, JG; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, KH; Kim, W; Park, JC, 2006) |
| "The current standard of care for patients with non-ST-segment elevation acute coronary syndromes (ACS) includes antithrombotic therapy with aspirin and heparin." | 3.71 | Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ( Antman, EM; Ball, SP; Becker, RC; Gibson, M; Murphy, SA; Rush, JE; Sanderink, G; Spencer, FA, 2002) |
| "(1) Enoxaparin and dalteparin are the only low-molecular-weight heparins so far approved for the treatment of unstable angina and non Q-wave myocardial infarction." | 3.70 | Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin. ( , 1999) |
| "(1) Aspirin reduces acute-phase mortality after myocardial infarction, and also reduces the risk of myocardial infarction and death in patients with unstable angina." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention. ( , 2000) |
| "In 256 patients participating in the FRISC trial, evaluating the effects of dalteparin (a low molecular weight heparin) in unstable angina or non-Q wave myocardial infarction, Chlamydia pneumoniae IgA antibody titres and levels of fibrinogen, C-reactive protein and troponin T were determined at inclusion." | 3.70 | Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. ( Gnarpe, H; Gnarpe, J; Lindahl, B; Siegbahn, A; Toss, H; Wallentin, L, 1998) |
| " Incremental IV dosing of enoxaparin (0." | 2.77 | Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. ( Armstrong, PW; Buller, CE; Gordon, P; O'Neill, B; Welsh, RC; Westerhout, CM, 2012) |
| "Dalteparin was effective and safe in primary PCI of STEMI patients and combined dalteparin with tirofiban was effective and safe without significant bleeding complications compared with UFH." | 2.76 | Comparison of tirofiban combined with dalteparin or unfractionated heparin in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction patients. ( Ge, YG; Li, WM; Ni, ZH; Wang, HS; Wang, LF; Xu, L; Yang, XC; Zhang, DP, 2011) |
| " The rates of in-hospital major adverse cardiac or cerebral events were 11." | 2.75 | Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registry. ( Afilalo, M; Dery, JP; Eisenberg, MJ; El-Rayes, M; Harvey, R; Huynh, T; Kouz, R; Kouz, S; Lauzon, C; Mansour, S; Nguyen, M; Rinfret, S; Schampaert, E; Tardif, JC; Van Kieu, AM, 2010) |
| "Although weight-based nomograms have improved the efficacy and safety of dosing unfractionated heparin in ST-segment elevation myocardial infarction, achieving therapeutic anticoagulation in practice remains challenging." | 2.74 | Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. ( Antman, EM; Cheng, S; Morrow, DA; Sabatine, MS; Sloan, S, 2009) |
| "Although appropriate anticoagulation is essential to maximize the efficacy and safety of primary PCI, the optimal dosing of enoxaparin in this setting is unclear." | 2.73 | A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. ( Armstrong, PW; Buller, CE; Gordon, P; O'Neill, B; Welsh, RC; Westerhout, CM, 2007) |
| " Elderly patients (> or = 75 years of age) received a novel enoxaparin dosing regimen and when compared with UFH, benefited from a lower relative bleeding risk than younger patients without compromising efficacy in preventing death or MI." | 2.73 | ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis. ( Gabriel, RS; White, HD, 2007) |
| " Adverse events were similar in the three groups." | 2.72 | A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study. ( Bhalla, A; Grover, A; Malhotra, S; Pandhi, P; Shafiq, N; Sharma, N, 2006) |
| " Since optimal dosing of subcutaneous Enoxaparin is not standardized, we conducted an observational study to compare safety and efficacy of low (4,000 U once daily) vs full dose (100 U/kg twice daily) regimens." | 2.72 | Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose. ( Gatti, C; Maresta, A; Parollo, R; Rubboli, A; Spinolo, L; Spitali, G, 2006) |
| "Rates of myocardial infarction were 141 (12." | 2.72 | 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. ( Husted, S; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2006) |
| " All patients were monitored for adverse clinical events (i." | 2.71 | [Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention]. ( Chen, JZ; Fu, GS; Huang, WJ; Qiu, YG; Shen, FR; Tao, QM; Wang, JA; Zhang, FR; Zhao, LL; Zheng, LR; Zhu, JH, 2005) |
| " A population pharmacokinetic analysis was conducted and individual estimates of enoxaparin clearance and area under the curve were tested as prognostic factors for the occurrence of haemorrhagic episodes." | 2.71 | Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. ( Antman, EM; Baille, P; Becker, R; Bruno, R; Retout, S; Sanderink, GJ; Veyrat-Follet, C; Vivier, N, 2003) |
| " It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors." | 2.71 | Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. ( Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD, 2004) |
| "More bleeding was observed with enoxaparin, with a statistically significant increase in TIMI (Thrombolysis in Myocardial Infarction) major bleeding (9." | 2.71 | Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. ( Antman, EM; Armstrong, PW; Avezum, A; Aylward, P; Becker, RC; Biasucci, L; Borzak, S; Califf, RM; Cohen, M; Col, J; Ferguson, JJ; Frey, MJ; Fry, E; Goodman, S; Grines, CL; Gulba, DC; Guneri, S; Gurfinkel, E; Harrington, R; Hochman, JS; Kereiakes, DJ; Kleiman, NS; Langer, A; Leon, MB; Lopez-Sendon, JL; Mahaffey, KW; Nessel, CC; Pepine, CJ; Ruzyllo, W; Steinhubl, SR; Teirstein, PS; Toro-Figueroa, L; White, H, 2004) |
| "Diabetes mellitus is a major contributor to CAD." | 2.71 | Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. ( Diderholm, E; Lagerqvist, B; Lindahl, B; Malmberg, K; Norhammar, A; Rydén, L; Wallentin, L, 2004) |
| "Prospective, randomized, double-blind study (POLENOX) proved that administration of low molecular weight heparin (LMWH)--enoxaparin for elective percutaneous coronary interventions (PCI) is as safe and as effective like unfractionated heparin (UFH)." | 2.71 | [Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine]. ( Bartuś, S; Chyrchel, M; Dubiel, JS; Dudek, D; Legutko, J; Rzeszutko, L, 2004) |
| "Pain was assessed with a 10-unit numeric scale." | 2.70 | Comparison of two needle sizes for subcutaneous administration of enoxaparin: effects on size of hematomas and pain on injection. ( Kanji, Z; Robb, DM, 2002) |
| " The second issue is whether early use of an aggressively dosed statin is superior to a current trial-based "accepted care" regimen of a lower-dose statin started 3 to 6 months after an acute event." | 2.70 | The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. ( Bilheimer, D; Blazing, MA; Braunwald, E; Califf, RM; De Lemos, JA; Dyke, CK, 2001) |
| "Patients with unstable angina pectoris (UAP) or non-ST-segment elevation acute myocardial infarction (AMI) are at risk of death or recurrent ischemic events, despite receiving aspirin and unfractionated heparin (UFH)." | 2.70 | Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. ( Berkowitz, SD; Bigonzi, F; Cohen, M; Fromell, GJ; Stinnett, S, 2001) |
| "In dalteparin-treated patients, delta vWf was elevated (+48 +/- 8%) and did not differ from the unfractionated heparin group (NS)." | 2.69 | Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. ( Ankri, A; Choussat, R; Collet, JP; Drobinski, G; Lison, L; Montalescot, G; Perlemuter, K; Philippe, F; Thomas, D; Vicaut, E, 2000) |
| "Fibrin formation was decreased by Parnaparin in a concentration-dependent way, according to both the anti-Xa activity and the APTT ratio." | 2.67 | Effects of two dosages of subcutaneous low molecular weight heparin (Parnaparin) and of unfractionated heparin on fibrin formation and lipolysis in acute myocardial infarction. ( Branzi, A; Cervi, V; Magnani, B; Melandri, G; Semprini, F, 1992) |
| " Dosing schedules based on pharmacodynamic and clinical data offer a seamless transition for enoxaparin from the medical management phase to PCI." | 2.47 | Use of low-molecular-weight heparins during percutaneous coronary intervention. ( Martin, JL; Slepian, M, 2011) |
| " Selection of the appropriate dosage is strongly recommended." | 2.45 | Safety evaluation of enoxaparin in currently approved indications. ( Meneveau, N, 2009) |
| "Dalteparin was superior to placebo on left ventricular thrombosis/arterial thromboembolism, with no significant effect on the early patency rate of the infarct-related artery (IRA)." | 2.44 | Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature. ( Brancaleoni, R; Capecchi, A; Galvani, M; Ottani, F; Rubboli, A; Swahn, E, 2007) |
| " Unlike its unfractionated heparin (UFH) counterparts, enoxaparin has a greater bioavailability, lower incidence of heparin-induced thrombocytopenia and more stable and predictable anticoagulation, allowing fixed dosing without the need for monitoring." | 2.44 | Enoxaparin in acute coronary syndromes. ( Gibson, CM; Lee, S, 2007) |
| " Careful attention to dosing and excellent vascular access site management after cardiac catheterization are required to decrease the risk of bleeding and blood transfusion, which have been associated with increased mortality risk." | 2.44 | New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction. ( Bates, ER, 2007) |
| "Fondaparinux was compared with enoxaparin or usual care, depending on the setting." | 2.44 | Efficacy and safety of fondaparinux in patients with acute coronary syndromes. ( Bassand, JP; Cadroy, Y; Richard-Lordereau, I, 2007) |
| "Fondaparinux has been shown to be as effective as enoxaparin in the prevention of thrombosis in patients undergoing orthopedic surgery and showed similar results compared to enoxaparin or UFH in patients with deep-vein-thrombosis or pulmonary embolism." | 2.44 | Factor Xa inactivation in acute coronary syndrome. ( Barantke, M; Bonnemeier, H, 2008) |
| " Further investigations as a basis of general recommendations on standard dosing regimen are outstanding for use of each LMWH in percutaneous coronary interventions, as combination with Glycoprotein IIb/IIIa-inhibitors, in acute myocardial infarction and in artificial heart valves." | 2.42 | Anticoagulation with low-molecular-weight heparin in patients with heart diseases. ( Bechtold, H; Janssen, D, 2004) |
| " Various clinical studies in unstable angina and acute coronary syndrome have proved that clivarine in a dosage of 3436anti-Xa units twice daily is an effective antithrombotic agent." | 2.42 | Reviparin sodium clivarine: a review of its therapeutic use. ( Gore, M; Kelkar, P; Rege, N; Ross, C, 2004) |
| " Compared to unfractionated heparins LMWH are user-friendly (high bioavailability after subcutaneous application, no needed routine control of plasma efficacy)." | 2.41 | [Low molecular weight heparins in acute coronary syndrome]. ( Huber, K; Niessner, A; Niessner, H, 2001) |
| " Future issues that need to be addressed include refinement of indications for administration and patient selection, comparison between existing agents, evaluation of newer agents, and optimization of dosing to maximize benefit and safety in the use of these powerful new classes of drugs." | 2.41 | Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. ( Vernon, SM, 2001) |
| " They are more predictable in action, do not require frequent activated partial thromboplastin time (aPTT) measurements and dosage adjustments, are easier to administer, and are potentially more efficacious." | 2.41 | Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. ( Monrad, ES, 2000) |
| "Therapy to prevent deep venous thrombosis (DVT) and pulmonary embolism remains essential for inpatients, despite short periods of bedrest and hospitalization." | 2.41 | Deep venous thrombosis prophylaxis in patients with heart disease. ( Shively, BK, 2001) |
| "Patients presenting with unstable angina pectoris or non-Q-wave myocardial infarction (MI), if treated inadequately, are at a high risk of MI and subsequent mortality." | 2.41 | Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial. ( Adgey, AA; Manoharan, G, 2002) |
| "Dalteparin sodium has been subjected to a large number of well-designed randomised clinical trials for the prevention and treatment of thrombotic disorders." | 2.41 | Dalteparin sodium. ( Hull, RD; Pineo, GF, 2001) |
| " Low-molecular-weight heparin provides more reliable anticoagulation and less need for patient monitoring and dosage adjustment than standard unfractionated heparin (UFH) and therefore is well suited for long-term anticoagulation on an outpatient basis." | 2.40 | TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction ( Antman, EM, 1998) |
| " Studies have shown that weight-based dosing influences significantly both the time to reach a therapeutic intensity of anticoagulation and the incidence of thromboembolic recurrence." | 2.39 | Contemporary use of and future roles for heparin in antithrombotic therapy. ( Gibaldi, M; Wittkowsky, AK, 1995) |
| "Risk of bleeding was assessed with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) scale, and risk of major bleeding in patients with NSTEMI was additionally assessed with the CRUSADE scale." | 1.72 | Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM. ( Boytsov, SA; Erlikh, AD; Gulyan, RG; Pevsner, DV; Shakhnovich, RM; Tereschenko, SN, 2022) |
| "Neonatal myocardial infarction is a rare clinical entity that is associated with high mortality." | 1.42 | A case of neonatal myocardial infarction: left coronary artery thrombus resolution and normalisation of ventricular function by intracoronary low-dose tissue plasminogen activator. ( Dori, Y; Gillespie, MJ; Hallbergson, A, 2015) |
| "We describe a patient with a giant thrombus on the apical wall of the left ventricle that occurred due to HIT syndrome after anterior myocardial infarction." | 1.40 | Giant thrombus on apical wall of left ventricle due to HIT syndrome after anterior MI. ( Balaban Kocas, B; Coskun, U; Gultekin, N; Gurmen, T; Kucukoglu, S; Sinan, UY, 2014) |
| "This is the first case of renal infarction that developed in the early hours of primary PCI, despite effective anticoagulant and antiplatelet treatment." | 1.36 | Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids. ( Calık, AN; Demirci, D; Güvenç, TS; Ilhan, E, 2010) |
| "Fondaparinux was found to be noninferior to enoxaparin and was associated with fewer bleeding events in the OASIS-5 study of patients who were not treated with an early invasive approach." | 1.35 | 2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies. ( Battistone, S; Coons, JC, 2008) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 1.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| " The ExTRACT-TIMI 25 trial employed a novel dosing regimen for enoxaparin adjusted for age and renal function, which was designed to minimize bleeding risk while maintaining the beneficial effects of enoxaparin." | 1.35 | ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. ( Giugliano, RP; Thomas, D, 2009) |
| "Acute myocardial infarction is a rare complication of mitral stenosis." | 1.33 | Acute myocardial infarction in a patient with severe unrecognized mitral stenosis. ( Bajraktari, G; Beqiri, A; Berisha, I; Elezi, S; Kastrati, S; Manaj, R; Thaqi, S, 2006) |
| " However, little dosing information is available regarding the use of enoxaparin in patients with renal impairment." | 1.33 | Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. ( Ankri, A; Collet, JP; Hulot, JS; Lechat, P; Montalescot, G; Urien, S, 2005) |
| "Unfractionated heparin (UFH) has been considered the standard anticoagulant for patients with non-ST-segment-elevation acute coronary syndromes (NSTE ACS), yet it has limitations, including an unpredictable dose-response and intravenous administration." | 1.33 | Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial. ( Goodman, S, 2005) |
| "We suppose that cocaine abuse may have had a delayed effect as trigger of acute myocardial infarction." | 1.33 | Acute myocardial infarction in a young woman with antiphospholipid syndrome and occasional cocaine abuse. ( Dei Cas, L; Pedrinazzi, C; Procopio, R; Raddino, R; Zanini, G, 2005) |
| "The use of intravenous enoxaparin, a glyco-protein (GP) IIb/IIIa inhibitor, during percutaneous coronary intervention (PCI) has been shown to be safe and to possibly reduce in-hospital and 30-day major adverse cardiac events(MACE)." | 1.32 | Safety and efficacy of low-dose intravenous enoxaparin and GP IIb/IIIa inhibitor therapy during PCI. ( Borkowski, R; Carnendran, L; Markabawi, B; Warner, MF, 2003) |
| "Subcutaneous Enoxaparin given at least for 48 hours before PCI with out additional UFH or LMWH during or after PCI was both safe and effective in high risk UA/NQMI patients." | 1.32 | [The safety and efficacy of pre-treatment with enoxaparin (Clexane) in acute coronary syndrome patients undergoing percutaneous coronary intervention]. ( Chen, BX; Hu, DY; Jia, SQ; Kong, FL; Li, TC; Wang, L; Zhao, H; Zhao, XL, 2003) |
| "The objective of this study was to evaluate the pharmacokinetic response to intravenous (IV) enoxaparin given 8-12 hr after subcutaneous (SC) dosing in patients undergoing percutaneous coronary intervention (PCI)." | 1.32 | Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. ( Atherley, TH; Bigonzi, F; Chevalier, PJ; Fry, ET; Guimart, CM; Martin, JL; Ozoux, ML; Pensyl, CE; Sanderink, GJ, 2004) |
| "To describe dosing practices and to identify risk factors for bleeding in patients with an acute coronary syndrome (ACS) who received treatment with enoxaparin." | 1.32 | Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. ( Douketis, JD; Forbes, L; Foster, GA; Macie, C, 2004) |
| "Enoxaparin seems to offer safe and effective procedural anticoagulation in patients undergoing percutaneous intervention for acute coronary syndromes." | 1.32 | Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes? ( Ayzenberg, Y; Cafri, C; Gilutz, H; Ilia, R; Wolak, A; Zahger, D, 2004) |
| "We address the problem of the choice and the evaluation of designs in population pharmacokinetic studies that use non-linear mixed-effects models." | 1.31 | Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. ( Bruno, R; Mentré, F; Retout, S, 2002) |
| "The aim of this trial, undertaken with the participation of 13 centres, was to establish the minimal effective dosage of nadroparin (Fraxiparin) for the prevention of left ventricular mural thrombosis in acute anterior myocardial infarction which was not treated by thrombolysis." | 1.30 | [Fraxiparin and prevention of left ventricular thrombosis in non-thrombolyzed myocardial infarction. FRATIV Study]. ( Charbonnier, B, 1997) |
| "Myocardial infarction was induced by ligating the left main coronary artery." | 1.29 | The effect of low molecular weight heparin (fragmin) on myocardial neutrophil accumulation and infarct size in a rat model of myocardial infarction. ( Battler, A; Blumberg, N; Hasdai, D; Kornowski, R; Ohad, D; Varda-Bloom, N, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.51) | 18.7374 |
| 1990's | 49 (12.53) | 18.2507 |
| 2000's | 284 (72.63) | 29.6817 |
| 2010's | 53 (13.55) | 24.3611 |
| 2020's | 3 (0.77) | 2.80 |
| Authors | Studies |
|---|---|
| Bassand, JP | 10 |
| Berthe, C | 1 |
| Bethencourt, A | 1 |
| Bolognese, L | 1 |
| Wójcik, J | 1 |
| Zhu, JH | 1 |
| Qiu, YG | 1 |
| Chen, JZ | 1 |
| Zhang, FR | 1 |
| Fu, GS | 1 |
| Shen, FR | 1 |
| Huang, WJ | 1 |
| Wang, JA | 1 |
| Zhao, LL | 1 |
| Tao, QM | 1 |
| Zheng, LR | 1 |
| Bajraktari, G | 1 |
| Kastrati, S | 1 |
| Manaj, R | 1 |
| Berisha, I | 1 |
| Thaqi, S | 1 |
| Beqiri, A | 1 |
| Elezi, S | 1 |
| Shafiq, N | 1 |
| Malhotra, S | 1 |
| Pandhi, P | 1 |
| Sharma, N | 1 |
| Bhalla, A | 1 |
| Grover, A | 1 |
| Elikowski, W | 1 |
| Psuja, P | 1 |
| Lewandowski, K | 1 |
| Przybył, M | 1 |
| Wendland, M | 1 |
| Wróblewski, D | 1 |
| Jazienicki, B | 1 |
| Przybył, L | 1 |
| Zawilska, K | 1 |
| Talley, JD | 1 |
| Charbonnier, B | 1 |
| Godoy, I | 1 |
| Herrera, C | 1 |
| Zapata, C | 1 |
| Kunstmann, S | 1 |
| Abufhele, A | 1 |
| Corbalán, R | 3 |
| Chamuleau, SA | 1 |
| de Winter, RJ | 1 |
| Levi, M | 2 |
| Adams, R | 1 |
| Büller, HR | 2 |
| Prins, MH | 1 |
| Lie, KI | 1 |
| Peters, RJ | 6 |
| Zed, PJ | 2 |
| Tisdale, JE | 1 |
| Borzak, S | 3 |
| Antman, EM | 49 |
| Cohen, M | 41 |
| Radley, D | 5 |
| McCabe, C | 2 |
| Rush, J | 1 |
| Premmereur, J | 4 |
| Braunwald, E | 28 |
| Kaul, S | 1 |
| Shah, PK | 2 |
| Borja, J | 4 |
| Olivella, P | 2 |
| Jiménez Martín, CM | 1 |
| Durán Quintana, JA | 1 |
| Abadín Delgado, JA | 1 |
| Cruz Fernández, JM | 1 |
| Sánchez Romero, A | 1 |
| Huber, K | 12 |
| Niessner, A | 1 |
| Niessner, H | 1 |
| Vernon, SM | 1 |
| Neagu, M | 1 |
| Manda, G | 1 |
| Constantin, C | 1 |
| Tanaseanu, C | 1 |
| Mikhailidis, DP | 1 |
| Ottani, F | 2 |
| Ferrini, D | 1 |
| Di Pasquale, G | 2 |
| Galvani, M | 2 |
| Zhang, Y | 2 |
| Wang, XK | 2 |
| Yang, CM | 2 |
| Liu, GY | 2 |
| Wang, Y | 1 |
| Melandri, G | 1 |
| Branzi, A | 1 |
| Semprini, F | 1 |
| Cervi, V | 1 |
| Magnani, B | 1 |
| Boytsov, SA | 3 |
| Shakhnovich, RM | 3 |
| Tereschenko, SN | 3 |
| Erlikh, AD | 3 |
| Pevsner, DV | 3 |
| Gulyan, RG | 3 |
| Rosenthal, N | 1 |
| Xiao, Z | 1 |
| Kartashov, A | 1 |
| Levorsen, A | 1 |
| Shah, BR | 1 |
| Vera, A | 1 |
| Rivero, F | 1 |
| Salamanca, J | 1 |
| Alvarado-Casas, T | 1 |
| Alfonso, F | 1 |
| De la Torre Hernández, JM | 1 |
| Sadaba Sagredo, M | 1 |
| Telleria Arrieta, M | 1 |
| Gimeno de Carlos, F | 1 |
| Sanchez Lacuesta, E | 1 |
| Bullones Ramírez, JA | 1 |
| Pineda Rocamora, J | 1 |
| Martin Yuste, V | 1 |
| Garcia Camarero, T | 1 |
| Larman, M | 1 |
| Rumoroso, JR | 1 |
| Li, ZZ | 1 |
| Tao, Y | 1 |
| Wang, S | 1 |
| Yin, CQ | 1 |
| Gao, YL | 1 |
| Cheng, YT | 1 |
| Li, Z | 1 |
| Ma, CS | 1 |
| Nafee, T | 1 |
| Gibson, CM | 13 |
| Yee, MK | 1 |
| Kerneis, M | 3 |
| Daaboul, Y | 1 |
| Korjian, S | 1 |
| Chi, G | 1 |
| Kalayci, A | 1 |
| Afzal, MK | 1 |
| Kazmi, H | 1 |
| Datta, S | 1 |
| AlKhalfan, F | 1 |
| Hernandez, AF | 1 |
| Hull, RD | 2 |
| Harrington, RA | 10 |
| Cohen, AT | 2 |
| Goldhaber, SZ | 2 |
| Armstrong, PW | 22 |
| Gershlick, AH | 2 |
| Goldstein, P | 12 |
| Wilcox, R | 2 |
| Danays, T | 4 |
| Lambert, Y | 1 |
| Sulimov, V | 1 |
| Rosell Ortiz, F | 1 |
| Ostojic, M | 2 |
| Welsh, RC | 9 |
| Carvalho, AC | 1 |
| Nanas, J | 1 |
| Arntz, HR | 3 |
| Halvorsen, S | 2 |
| Grajek, S | 1 |
| Fresco, C | 2 |
| Bluhmki, E | 2 |
| Regelin, A | 1 |
| Vandenberghe, K | 1 |
| Bogaerts, K | 4 |
| Van de Werf, F | 14 |
| Vavalle, JP | 1 |
| Clare, R | 1 |
| Chiswell, K | 1 |
| Rao, SV | 2 |
| Petersen, JL | 4 |
| Kleiman, NS | 8 |
| Mahaffey, KW | 16 |
| Wang, TY | 1 |
| Backman, WD | 1 |
| Bakhai, A | 1 |
| Sinan, UY | 1 |
| Coskun, U | 1 |
| Balaban Kocas, B | 1 |
| Gultekin, N | 1 |
| Gurmen, T | 1 |
| Kucukoglu, S | 1 |
| Collet, JP | 14 |
| Zeymer, U | 10 |
| Pollack, C | 4 |
| Silvain, J | 7 |
| Henry, P | 1 |
| Varenne, O | 1 |
| Carrié, D | 2 |
| Coste, P | 4 |
| Angioi, M | 1 |
| Le Breton, H | 1 |
| Cayla, G | 4 |
| Elhadad, S | 2 |
| Teiger, E | 2 |
| Filippi, E | 2 |
| Aout, M | 2 |
| Vicaut, E | 8 |
| Montalescot, G | 22 |
| Ramos-Esquivel, A | 1 |
| Salazar-Sánchez, L | 1 |
| Clemens, A | 1 |
| Fraessdorf, M | 1 |
| Friedman, J | 1 |
| Hallbergson, A | 1 |
| Gillespie, MJ | 1 |
| Dori, Y | 1 |
| Puymirat, E | 1 |
| Schiele, F | 1 |
| Ennezat, PV | 1 |
| Bonnefoy-Cudraz, E | 1 |
| Roul, G | 1 |
| Richard, P | 1 |
| Simon, T | 1 |
| Danchin, N | 3 |
| Squizzato, A | 1 |
| Lussana, F | 1 |
| Cattaneo, M | 1 |
| Mele, M | 1 |
| Martimucci, M | 1 |
| Maggi, A | 1 |
| Villella, A | 1 |
| Villella, M | 1 |
| Langialonga, T | 1 |
| Bugiardini, R | 1 |
| Dorobantu, M | 5 |
| Vasiljevic, Z | 1 |
| Kedev, S | 1 |
| Knežević, B | 1 |
| Miličić, D | 1 |
| Calmac, L | 1 |
| Trninic, D | 1 |
| Daullxhiu, I | 1 |
| Cenko, E | 1 |
| Ricci, B | 1 |
| Puddu, PE | 1 |
| Manfrini, O | 1 |
| Koller, A | 1 |
| Badimon, L | 1 |
| Pellaton, C | 1 |
| Bainey, KR | 1 |
| Zheng, Y | 1 |
| Carvalho, A | 1 |
| Westerhout, CM | 3 |
| Liu, Z | 1 |
| Barthélémy, O | 3 |
| Payot, L | 2 |
| Choussat, R | 8 |
| Sabouret, P | 1 |
| Pollack, CV | 3 |
| Schinzel, H | 1 |
| Mazhar, F | 1 |
| Ahmed, Y | 1 |
| Mayer, M | 1 |
| Hollander, JE | 1 |
| Coons, JC | 1 |
| Battistone, S | 1 |
| Leung, S | 1 |
| Gallup, D | 1 |
| Goodman, SG | 22 |
| Langer, A | 15 |
| Aylward, P | 2 |
| Ferguson, JJ | 13 |
| Califf, RM | 18 |
| Khoobiar, S | 1 |
| Mejevoi, N | 1 |
| Kaid, K | 1 |
| Boiangiu, C | 1 |
| Setty, S | 1 |
| Tanwir, A | 1 |
| Khalid, K | 1 |
| Ibrahim, K | 1 |
| Hass, N | 1 |
| Kolschmann, S | 1 |
| Strasser, RH | 1 |
| Braun-Dullaeus, RC | 1 |
| Pride, YB | 1 |
| Aylward, PE | 6 |
| Col, JJ | 4 |
| Gulba, D | 1 |
| Bergovec, M | 1 |
| Kunadian, V | 1 |
| Zorkun, C | 1 |
| Buros, JL | 1 |
| Murphy, SA | 16 |
| Budaj, A | 8 |
| Eikelboom, JW | 6 |
| Mehta, SR | 8 |
| Afzal, R | 5 |
| Chrolavicius, S | 6 |
| Fox, KA | 20 |
| Wallentin, L | 34 |
| Granger, CB | 14 |
| Joyner, CD | 1 |
| Yusuf, S | 8 |
| Carter, NJ | 2 |
| McCormack, PL | 2 |
| Plosker, GL | 2 |
| Thomas, D | 7 |
| Giugliano, RP | 7 |
| Boden, WE | 1 |
| Flather, M | 1 |
| Steg, PG | 5 |
| Avezum, A | 3 |
| Piegas, LS | 2 |
| Faxon, DP | 2 |
| Widimsky, P | 1 |
| Rupprecht, HJ | 1 |
| Jolly, S | 2 |
| Bernardon, M | 1 |
| Limone, A | 1 |
| Businelli, C | 1 |
| Maso, GP | 1 |
| Piccoli, M | 1 |
| Alberico, S | 1 |
| Christy, GW | 1 |
| Cheng, S | 1 |
| Morrow, DA | 20 |
| Sloan, S | 1 |
| Sabatine, MS | 6 |
| Gitt, A | 3 |
| Zahn, R | 3 |
| Jünger, C | 3 |
| Bauer, T | 2 |
| Heer, T | 2 |
| Koeth, O | 3 |
| Senges, J | 4 |
| Karthikeyan, G | 1 |
| Schwarz, AK | 1 |
| Quinlan, DJ | 1 |
| Giraldez, RR | 3 |
| Wiviott, SD | 3 |
| Nicolau, JC | 4 |
| Mohanavelu, S | 4 |
| Marcoff, L | 1 |
| Zhang, Z | 2 |
| Zhang, W | 1 |
| Ewen, E | 1 |
| Jurkovitz, C | 1 |
| Leguet, P | 1 |
| Kolm, P | 2 |
| Weintraub, WS | 2 |
| Meneveau, N | 1 |
| Gallo, R | 5 |
| White, HD | 21 |
| Bode, C | 2 |
| Chiariello, M | 1 |
| King, SB | 2 |
| Desmet, WJ | 2 |
| Macaya, C | 2 |
| Steinhubl, SR | 6 |
| Brener, SJ | 2 |
| Sauriol, L | 1 |
| Theroux, P | 6 |
| Steg, G | 1 |
| Li, YJ | 2 |
| Rha, SW | 2 |
| Chen, KY | 2 |
| Poddar, KL | 2 |
| Jin, Z | 2 |
| Minami, Y | 2 |
| Wang, L | 3 |
| Dang, Q | 1 |
| Li, GP | 1 |
| Ramasamy, S | 2 |
| Park, JY | 2 |
| Choi, CU | 3 |
| Kim, JW | 1 |
| Kim, EJ | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Oh, DJ | 2 |
| Jeong, MH | 3 |
| Ahn, YK | 2 |
| Hong, TJ | 1 |
| Park, JS | 1 |
| Kim, YJ | 1 |
| Hur, SH | 1 |
| Seong, IW | 1 |
| Chae, JK | 1 |
| Cho, MC | 1 |
| Bae, JH | 1 |
| Choi, DH | 1 |
| Jang, YS | 1 |
| Chae, IH | 2 |
| Kim, HS | 1 |
| Kim, CJ | 1 |
| Yoon, JH | 1 |
| Ahn, TH | 1 |
| Tahk, SJ | 1 |
| Chung, WS | 1 |
| Seung, KB | 1 |
| Park, SJ | 1 |
| Giugliano, R | 1 |
| McCabe, CH | 13 |
| Menown, I | 1 |
| Pal, N | 1 |
| Fidler, C | 1 |
| Orme, M | 1 |
| Gillard, S | 1 |
| Sinnaeve, P | 1 |
| Brieger, D | 3 |
| Landivier, A | 1 |
| Beygui, F | 4 |
| Bellemain-Appaix, A | 1 |
| Mercadier, A | 1 |
| Vignolles, N | 3 |
| Costagliola, D | 1 |
| Gershlick, A | 1 |
| Nammas, W | 1 |
| Hossam, K | 1 |
| Anusionwu, OF | 1 |
| Shah, N | 1 |
| El-Rayes, M | 1 |
| Schampaert, E | 1 |
| Tardif, JC | 1 |
| Eisenberg, MJ | 2 |
| Afilalo, M | 1 |
| Kouz, S | 1 |
| Lauzon, C | 1 |
| Harvey, R | 1 |
| Nguyen, M | 1 |
| Kouz, R | 1 |
| Dery, JP | 1 |
| Mansour, S | 1 |
| Van Kieu, AM | 1 |
| Rinfret, S | 1 |
| Huynh, T | 2 |
| Ilhan, E | 1 |
| Demirci, D | 1 |
| Güvenç, TS | 1 |
| Calık, AN | 1 |
| Martin, JL | 2 |
| Slepian, M | 1 |
| Wong, CK | 1 |
| Moliterno, DJ | 3 |
| Pieper, KS | 2 |
| Lokhnygina, Y | 2 |
| Hochman, JS | 2 |
| Roe, MT | 2 |
| Caruso, M | 1 |
| Bracale, UM | 1 |
| Incalcaterra, E | 1 |
| Vitale, G | 1 |
| Bajardi, G | 1 |
| Assennato, P | 1 |
| Hoffmann, E | 1 |
| Novo, S | 1 |
| Stone, GW | 4 |
| Ohman, EM | 1 |
| Boulanger, B | 1 |
| Ecollan, P | 1 |
| Combes, X | 1 |
| Bénezet, JF | 1 |
| Stibbe, O | 1 |
| Adnet, F | 1 |
| Chouihed, T | 1 |
| Gallula, S | 1 |
| Greffet, A | 1 |
| Rahman, MS | 1 |
| Soo, L | 1 |
| Qasim, A | 1 |
| Lavi, S | 1 |
| Cantor, WJ | 3 |
| Casanova, A | 1 |
| Tan, MK | 1 |
| Yan, AT | 2 |
| Džavík, V | 2 |
| Fitchett, D | 4 |
| Cohen, EA | 1 |
| Borgundvaag, B | 1 |
| Heffernan, M | 2 |
| Ducas, J | 2 |
| James, S | 1 |
| Buller, CE | 3 |
| O'Neill, B | 2 |
| Gordon, P | 2 |
| Leonardi, S | 1 |
| Thomas, L | 1 |
| Neely, ML | 1 |
| Tricoci, P | 2 |
| Lopes, RD | 1 |
| Newby, LK | 2 |
| Gerbaud, E | 1 |
| Seguy, B | 1 |
| Bacci, MR | 1 |
| Santos, JA | 1 |
| Nogueira, LF | 1 |
| Namura, JJ | 1 |
| Rott, D | 1 |
| Leibowitz, D | 1 |
| Chen, WH | 1 |
| Lau, CP | 1 |
| Lau, YK | 1 |
| Ng, W | 1 |
| Lee, PY | 1 |
| Yu, CM | 1 |
| Ma, E | 1 |
| White, H | 4 |
| Simoons, M | 1 |
| Krzemiñska-Pakula, M | 3 |
| Alonso, A | 1 |
| Goodman, S | 5 |
| Kali, A | 1 |
| Loos, U | 1 |
| Gosset, F | 1 |
| Louer, V | 1 |
| Bigonzi, F | 12 |
| Robb, DM | 1 |
| Kanji, Z | 1 |
| Retout, S | 2 |
| Mentré, F | 1 |
| Bruno, R | 2 |
| Cannon, CP | 6 |
| Curto, J | 1 |
| Campbell, J | 2 |
| Paz, MA | 1 |
| Jones, HU | 1 |
| Muhlestein, JB | 1 |
| Jones, KW | 1 |
| Bair, TL | 1 |
| Lavasani, F | 1 |
| Sohrevardi, M | 1 |
| Horne, BD | 1 |
| Doty, D | 1 |
| Lappe, DL | 1 |
| Aslam, MS | 1 |
| Sundberg, S | 1 |
| Sabri, MN | 1 |
| Cooke, D | 1 |
| Lakier, JB | 1 |
| Ozdemir, M | 1 |
| Erdem, G | 1 |
| Türkoglu, S | 1 |
| Cemri, M | 1 |
| Timurkaynak, T | 1 |
| Boyaci, B | 1 |
| Ridvan, Y | 1 |
| Cengel, A | 1 |
| Dörtlemez, O | 1 |
| Dörtlemez, H | 1 |
| Fine, E | 1 |
| Golmard, JL | 2 |
| Dalby, M | 3 |
| Ankri, A | 6 |
| Dumaine, R | 2 |
| Lesty, C | 1 |
| Durrleman, S | 1 |
| Chaikin, P | 1 |
| Monroe, VS | 1 |
| Kerensky, RA | 1 |
| Rivera, E | 1 |
| Smith, KM | 1 |
| Pepine, CJ | 3 |
| Bal-dit-Sollier, C | 1 |
| Chibedi, D | 1 |
| Soulat, T | 2 |
| Cohen, A | 1 |
| Slama, M | 1 |
| Dubois-Randé, JL | 1 |
| Metzger, JP | 1 |
| Tarragano, F | 1 |
| Guermonprez, JL | 1 |
| Drouet, L | 2 |
| Carnendran, L | 1 |
| Borkowski, R | 1 |
| Markabawi, B | 1 |
| Warner, MF | 1 |
| Gruberg, L | 1 |
| Beyar, R | 1 |
| Hu, DY | 1 |
| Zhao, XL | 1 |
| Jia, SQ | 1 |
| Li, TC | 1 |
| Zhao, H | 1 |
| Kong, FL | 1 |
| Chen, BX | 1 |
| Veerappan, B | 1 |
| Latif, F | 1 |
| Patibandla, S | 1 |
| Hennebry, T | 1 |
| Ghani, M | 1 |
| Saucedo, J | 1 |
| Schechter, E | 1 |
| Sadanandan, S | 1 |
| Adgey, AA | 2 |
| Lindahl, B | 12 |
| Mäkijärvi, M | 2 |
| Verheugt, F | 2 |
| Spinler, SA | 2 |
| Inverso, SM | 1 |
| Stringer, KA | 1 |
| Michalis, LK | 2 |
| Katsouras, CS | 1 |
| Papamichael, N | 2 |
| Adamides, K | 2 |
| Naka, KK | 2 |
| Goudevenos, J | 1 |
| Sideris, DA | 2 |
| Bijsterveld, NR | 1 |
| Moons, AH | 1 |
| Meijers, JC | 1 |
| Wagner, G | 1 |
| Granger, C | 1 |
| Fu, Y | 1 |
| Baille, P | 1 |
| Vivier, N | 1 |
| Veyrat-Follet, C | 1 |
| Sanderink, GJ | 2 |
| Becker, R | 1 |
| Dubois, CL | 1 |
| Belmans, A | 2 |
| Fioretti, PM | 1 |
| López-Sendón, JL | 3 |
| Verheugt, FW | 5 |
| Meyer, J | 1 |
| Rubboli, A | 4 |
| Herzfeld, I | 1 |
| Maresta, A | 2 |
| Gensini, GF | 3 |
| Maritz, F | 3 |
| Gurfinkel, EP | 12 |
| Timerman, A | 3 |
| Santopinto, J | 4 |
| Hecquet, C | 2 |
| Vittori, L | 3 |
| Herrmann, HC | 1 |
| Bates, ER | 4 |
| Every, NR | 1 |
| Bosanquet, N | 1 |
| Jönsson, B | 1 |
| Bal dit Sollier, C | 1 |
| Gallois, V | 2 |
| Drobinski, G | 3 |
| Tatu-Chitoiu, G | 4 |
| Teodorescu, C | 3 |
| Dan, M | 3 |
| Capraru, P | 3 |
| Guran, M | 3 |
| Istratescu, O | 3 |
| Tatu-Chitoiu, A | 3 |
| Bumbu, A | 3 |
| Fry, ET | 2 |
| Atherley, TH | 1 |
| Guimart, CM | 1 |
| Chevalier, PJ | 1 |
| Ozoux, ML | 1 |
| Pensyl, CE | 1 |
| Slepian, MJ | 1 |
| Lev, EI | 1 |
| Hasdai, D | 3 |
| Scapa, E | 1 |
| Tobar, A | 1 |
| Assali, A | 1 |
| Lahav, J | 1 |
| Battler, A | 2 |
| Badimon, JJ | 1 |
| Kornowski, R | 3 |
| Tanguy, ML | 2 |
| Ellis, SG | 1 |
| Armstrong, P | 2 |
| Betriu, A | 1 |
| Brodie, B | 1 |
| Herrmann, H | 1 |
| Neumann, FJ | 1 |
| Smith, JJ | 1 |
| Topol, E | 1 |
| Shimpo, M | 1 |
| Weinberg, EO | 1 |
| Lee, RT | 1 |
| Macie, C | 1 |
| Forbes, L | 1 |
| Foster, GA | 1 |
| Douketis, JD | 1 |
| Adgey, J | 2 |
| Bestilny, SA | 1 |
| Sinnaeve, PR | 1 |
| Alexander, JH | 2 |
| Adgey, JA | 1 |
| Tendera, M | 1 |
| Diaz, R | 1 |
| Soares-Piegas, L | 1 |
| Vahanian, A | 1 |
| Van De Werf, FJ | 1 |
| Bechtold, H | 2 |
| Janssen, D | 1 |
| Gratsianskiĭ, NA | 2 |
| Alesh De Konto, A | 1 |
| Zuniga, MA | 1 |
| Enar, R | 1 |
| Akhmed Sheĭkh, C | 1 |
| Makarie, K | 1 |
| Blazing, MA | 3 |
| de Lemos, JA | 4 |
| Ardissino, D | 2 |
| DiBattiste, PM | 1 |
| Palmisano, J | 1 |
| Bilheimer, DW | 1 |
| Snapinn, SM | 1 |
| Ramsey, KE | 1 |
| Gardner, LH | 1 |
| Hasselblad, V | 3 |
| Pfeffer, MA | 1 |
| Lewis, EF | 1 |
| Grines, CL | 1 |
| Kereiakes, DJ | 1 |
| Nessel, CC | 3 |
| Becker, RC | 5 |
| Biasucci, L | 1 |
| Col, J | 1 |
| Frey, MJ | 1 |
| Fry, E | 1 |
| Gulba, DC | 4 |
| Guneri, S | 3 |
| Gurfinkel, E | 3 |
| Harrington, R | 1 |
| Leon, MB | 1 |
| Ruzyllo, W | 1 |
| Teirstein, PS | 1 |
| Toro-Figueroa, L | 2 |
| Le-Moigne-Amrani, A | 1 |
| Das, P | 2 |
| Chioncel, V | 1 |
| Wolak, A | 1 |
| Ayzenberg, Y | 1 |
| Cafri, C | 1 |
| Gilutz, H | 1 |
| Ilia, R | 1 |
| Zahger, D | 1 |
| Marian, AJ | 1 |
| Lansky, AJ | 2 |
| Lincoff, AM | 2 |
| Hazen, SL | 1 |
| Tate, L | 1 |
| Reist, CJ | 2 |
| Tiu, A | 1 |
| Pang, JM | 1 |
| Martin, R | 1 |
| Officer, N | 1 |
| Kanna, B | 1 |
| Sharma, P | 1 |
| Pedrini, M | 1 |
| Hartig, F | 1 |
| Pechlaner, C | 1 |
| Bertrand, M | 1 |
| Colombo, A | 1 |
| Dangas, G | 1 |
| Farkouh, ME | 1 |
| Feit, F | 1 |
| Mehran, R | 1 |
| Moses, JW | 1 |
| Ohman, M | 1 |
| Oprişan, M | 1 |
| Cismara, O | 1 |
| Marinescu, R | 1 |
| Marinescu, A | 1 |
| Mukherjee, D | 1 |
| Ray, KK | 1 |
| Murphy, S | 1 |
| Väisänen, O | 1 |
| Silfvast, T | 1 |
| Willan, AR | 2 |
| Pinto, EM | 1 |
| O'Brien, BJ | 2 |
| Kaul, P | 2 |
| Goeree, R | 1 |
| Lynd, L | 1 |
| Chang, W | 1 |
| Jiang, F | 2 |
| Sharma, D | 1 |
| Chew, P | 1 |
| Nessel, CO | 1 |
| Welsh, R | 1 |
| Dobesh, P | 1 |
| Galla, JM | 1 |
| Hulot, JS | 1 |
| Lechat, P | 1 |
| Urien, S | 1 |
| Cowper, PA | 1 |
| Eisenstein, EL | 1 |
| Mark, DB | 1 |
| Topol, EJ | 2 |
| Katsouras, C | 1 |
| Nikas, D | 1 |
| Goudevenos, JA | 1 |
| Tan, DS | 1 |
| Sim, DK | 1 |
| Chan, ES | 1 |
| Tan, RS | 1 |
| Raddino, R | 1 |
| Pedrinazzi, C | 1 |
| Zanini, G | 1 |
| Procopio, R | 1 |
| Dei Cas, L | 1 |
| Garg, J | 1 |
| Antman, E | 1 |
| Berdan, LG | 2 |
| Joyner, C | 2 |
| Slavina, NN | 1 |
| Averkov, OV | 1 |
| Buckmaster, ND | 1 |
| Heazlewood, V | 1 |
| Scott, IA | 1 |
| Jones, M | 1 |
| Haerer, W | 1 |
| Hillier, K | 1 |
| Labèque, JN | 1 |
| Jaïs, C | 1 |
| Dubos, O | 1 |
| Denard, M | 1 |
| Berhouet, M | 1 |
| Leroux, L | 1 |
| Laplace, G | 1 |
| Vergnes, C | 1 |
| Pradeau, C | 1 |
| Thicoïpe, M | 1 |
| Dos Santos, P | 1 |
| White, JM | 1 |
| Munn, SE | 1 |
| Seet, JE | 1 |
| Adams, N | 1 |
| Clement, M | 1 |
| Fitchett, DH | 1 |
| Tan, M | 4 |
| Mendelsohn, A | 2 |
| Gatti, C | 1 |
| Spinolo, L | 1 |
| Parollo, R | 1 |
| Spitali, G | 1 |
| Pogue, J | 1 |
| Gibbons, RJ | 1 |
| Fuster, V | 2 |
| Ruda, M | 4 |
| Sadowski, Z | 2 |
| Bozovich, GE | 4 |
| Dos Santos, A | 1 |
| Svensson, L | 1 |
| Aasa, M | 1 |
| Dellborg, M | 3 |
| Kirtane, A | 1 |
| Herlitz, J | 1 |
| Ohlsson, A | 1 |
| Karlsson, T | 1 |
| Grip, L | 1 |
| Aggarwal, A | 1 |
| Brügger-Andersen, T | 1 |
| Hetland, Ø | 1 |
| Pönitz, V | 1 |
| Grundt, H | 1 |
| Nilsen, DW | 1 |
| Chang, WC | 1 |
| Bailey, AL | 1 |
| Pate, GE | 1 |
| O'Neill, BJ | 1 |
| Webb, JG | 1 |
| Rodríguez, A | 1 |
| Vallano, A | 1 |
| Palabrica, TM | 1 |
| Jennings, LK | 1 |
| Stone, PH | 1 |
| Lui, HH | 1 |
| Bulle, T | 1 |
| Lakkis, N | 1 |
| Kovach, R | 1 |
| Cohen, DJ | 1 |
| Fish, P | 1 |
| Wienbergen, H | 2 |
| Gottwik, M | 1 |
| Majure, DT | 1 |
| Aberegg, SK | 1 |
| DeCarolis, DD | 1 |
| Sleight, P | 1 |
| Capecchi, A | 2 |
| Brancaleoni, R | 1 |
| Swahn, E | 10 |
| Waksman, R | 1 |
| Wolfram, RM | 1 |
| Torguson, RL | 1 |
| Okubagzi, P | 1 |
| Xue, Z | 1 |
| Suddath, WO | 1 |
| Satler, LF | 1 |
| Kent, KM | 1 |
| Pieper, K | 1 |
| Hoekstra, J | 1 |
| Burnstein, J | 1 |
| Choi, R | 1 |
| Lazzam, C | 1 |
| Duic, M | 1 |
| Wawrzyniak, J | 1 |
| Kassam, S | 1 |
| Dhingra, S | 1 |
| Morrison, LJ | 1 |
| Darius, H | 1 |
| Huang, Z | 2 |
| Glezer, S | 1 |
| Chisholm, RJ | 1 |
| Bhatt, DL | 1 |
| Oliveira, GB | 1 |
| Anderson, FA | 1 |
| Dabbous, OH | 1 |
| Goldberg, RJ | 1 |
| Gore, JM | 1 |
| Helft, G | 1 |
| Castle, N | 1 |
| Porter, C | 1 |
| Thompson, B | 1 |
| Jacob, AJ | 2 |
| Gotcheva, N | 1 |
| Polonetsky, L | 1 |
| Lee, S | 1 |
| Mega, JL | 1 |
| Ostör, E | 1 |
| Qin, J | 2 |
| Chung, WY | 1 |
| Han, MJ | 1 |
| Cho, YS | 1 |
| Kim, KI | 1 |
| Chang, HJ | 1 |
| Youn, TJ | 1 |
| Choi, DJ | 1 |
| Kim, CH | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Choi, YS | 1 |
| Kracoff, OH | 1 |
| Lewis, BS | 1 |
| Roguin, N | 1 |
| Agewall, S | 1 |
| SomaRaju, B | 1 |
| Lopez-Sendon, J | 3 |
| Hod, H | 1 |
| Dalby, A | 1 |
| Pfisterer, M | 1 |
| Duris, T | 1 |
| Gao, R | 1 |
| Juarez, U | 1 |
| Parkhomenko, A | 2 |
| Molhoek, P | 2 |
| Steinberg, BA | 1 |
| Moghbeli, N | 1 |
| Buros, J | 1 |
| Raju, BS | 1 |
| García-Castillo, A | 1 |
| Janion, M | 1 |
| Agati, L | 1 |
| Funaro, S | 1 |
| Madonna, M | 1 |
| Sardella, G | 1 |
| Garramone, B | 1 |
| Galiuto, L | 1 |
| Menown, IB | 2 |
| Scirica, BM | 1 |
| Shui, A | 1 |
| Despotovic, N | 2 |
| Erceg, P | 1 |
| Nikolic-Despotovic, M | 2 |
| Milosevic, DP | 1 |
| Davidovic, M | 1 |
| Valentin, V | 1 |
| Moccetti, T | 1 |
| Friedewald, VE | 1 |
| Roberts, WC | 1 |
| Gabriel, RS | 1 |
| Owen, A | 1 |
| Ruff, CT | 1 |
| Richard-Lordereau, I | 1 |
| Cadroy, Y | 1 |
| Loncar, G | 1 |
| Ilicć, M | 1 |
| Dimković, S | 1 |
| Normand, SL | 1 |
| Diercks, DB | 1 |
| Kontos, MC | 1 |
| Weber, JE | 1 |
| Amsterdam, EA | 1 |
| Chew, DP | 1 |
| Aylward, PG | 1 |
| Salette, G | 1 |
| Camacho Pulido, JA | 1 |
| Jiménez Sánchez, JM | 1 |
| Montijano Vizcaíno, A | 1 |
| Jurado Lara, B | 1 |
| de Molina Ortega, A | 1 |
| Fernández-Meré, LA | 1 |
| Fernández Rogríguez, S | 1 |
| Alvarez-Blanco, M | 1 |
| Barantke, M | 1 |
| Bonnemeier, H | 1 |
| Grozovski, ES | 1 |
| Cohen, JD | 1 |
| Grunberg, G | 1 |
| Keslin, J | 1 |
| Gassner, S | 1 |
| Gibaldi, M | 1 |
| Wittkowsky, AK | 1 |
| Glick, A | 1 |
| Michowich, Y | 1 |
| Koifman, B | 1 |
| Roth, A | 1 |
| Laniado, S | 1 |
| Keren, G | 1 |
| Demers, C | 3 |
| Turpie, AG | 9 |
| Fromell, GJ | 4 |
| Massie, BM | 1 |
| Sacks, DB | 1 |
| Rifai, N | 1 |
| Noble, S | 1 |
| Spencer, CM | 1 |
| Philippe, F | 2 |
| Bearez, E | 1 |
| Poulard, JE | 1 |
| Flammang, D | 1 |
| Dutoit, A | 1 |
| Carayon, A | 1 |
| Jardel, C | 1 |
| Chevrot, M | 1 |
| Bastard, JP | 1 |
| Berger, PB | 1 |
| Bell, MR | 1 |
| Grill, DE | 1 |
| Melby, S | 1 |
| Holmes, DR | 2 |
| Panchenko, EP | 1 |
| Bernink, PJ | 3 |
| Salein, D | 2 |
| Bayes De Luna, A | 2 |
| Fox, K | 1 |
| Lablanche, JM | 2 |
| Purcell, H | 1 |
| Fox, KM | 2 |
| Iavelov, IS | 1 |
| Weber, S | 1 |
| Laramée, P | 1 |
| Diodati, JG | 1 |
| Squire, IB | 1 |
| Deckelbaum, LI | 1 |
| Thornton, AR | 1 |
| Harris, KE | 1 |
| Sax, FL | 1 |
| Lo, MW | 1 |
| Hilpert, U | 1 |
| Spencer, FA | 2 |
| Ball, SP | 2 |
| Zhang, Q | 1 |
| Liu, L | 2 |
| Benoit, S | 1 |
| Wang, JC | 1 |
| Popma, JJ | 1 |
| Monrad, ES | 1 |
| Quispe, A | 1 |
| Strinna, A | 1 |
| Mautner, B | 4 |
| Ross, AM | 2 |
| Coyne, K | 2 |
| Hammond, M | 1 |
| Lundergan, CF | 1 |
| Lison, L | 1 |
| Perlemuter, K | 1 |
| Horacek, T | 1 |
| Papuchis, G | 1 |
| Radley, DR | 2 |
| Le Iouer, V | 1 |
| Furst, J | 1 |
| Harvey, DM | 1 |
| Offord, RH | 1 |
| Gibler, WB | 1 |
| Willerson, JT | 1 |
| Barr, A | 1 |
| Sobtchouk, A | 1 |
| Laperrière, L | 1 |
| Hill, C | 1 |
| Le-Louer, V | 1 |
| Shively, BK | 1 |
| Nahlawi, M | 1 |
| Benzuly, K | 1 |
| Fintel, D | 1 |
| Torres, V | 1 |
| Marcos, E | 1 |
| Holper, EM | 1 |
| Dyke, CK | 1 |
| Bilheimer, D | 1 |
| Lundergan, C | 1 |
| Knudtson, M | 1 |
| Draoui, Y | 1 |
| Regalado, L | 1 |
| Le Louer, V | 1 |
| Schwartz, W | 1 |
| de Jong, E | 1 |
| Henry, TD | 1 |
| Satran, D | 1 |
| Knox, LL | 1 |
| Iacarella, CL | 1 |
| Laxson, DD | 1 |
| Alikhan, R | 1 |
| Córdoba López, A | 1 |
| Bueno Alvarez-Arenas, MI | 1 |
| Monterrubio Villar, J | 1 |
| Corcho Sánchez, G | 1 |
| Salvioni, A | 1 |
| Casilli, F | 1 |
| Assanelli, E | 1 |
| Grazi, M | 1 |
| Marenzi, G | 1 |
| Guazzi, MD | 1 |
| Nicholson, T | 1 |
| McGuire, A | 1 |
| Milne, R | 1 |
| Berkowitz, SD | 1 |
| Stinnett, S | 1 |
| Hobbach, HP | 1 |
| Schuster, P | 1 |
| Barragan, P | 1 |
| Teuma, X | 1 |
| Botosezzy, I | 1 |
| Bouvier, JL | 1 |
| Comet, B | 1 |
| Commeau, P | 1 |
| Macaluso, G | 1 |
| Roquebert, PO | 1 |
| Hödl, R | 1 |
| Kraxner, W | 1 |
| Nikfardjam, M | 1 |
| Schumacher, M | 1 |
| Fruhwald, FM | 1 |
| Zorn, G | 1 |
| Wonisch, M | 1 |
| Klein, W | 3 |
| Louwerenburg, HW | 1 |
| Baars, HF | 1 |
| Wesdorp, JC | 1 |
| Hamer, B | 1 |
| Pisapia, G | 1 |
| Heidbuchel, H | 1 |
| Baird, SH | 1 |
| Mcbride, SJ | 1 |
| Trouton, TG | 1 |
| Wilson, C | 1 |
| Vivekananthan, DP | 1 |
| Solanki, V | 1 |
| Gaynor, M | 1 |
| Booth, V | 1 |
| MacDonald, R | 1 |
| Freedman, SB | 1 |
| Massel, D | 1 |
| Cruickshank, MK | 1 |
| Gibson, M | 1 |
| Rush, JE | 1 |
| Sanderink, G | 1 |
| Xie, C | 1 |
| Ahmed, RJ | 1 |
| Xavier, D | 1 |
| Pais, P | 1 |
| Zhu, J | 1 |
| Gore, M | 1 |
| Kelkar, P | 1 |
| Rege, N | 1 |
| Ross, C | 1 |
| Yan, RT | 1 |
| Buccelletti, F | 1 |
| Li, WM | 1 |
| Yang, XC | 1 |
| Wang, LF | 1 |
| Ge, YG | 1 |
| Wang, HS | 1 |
| Xu, L | 1 |
| Ni, ZH | 1 |
| Zhang, DP | 1 |
| Wang, CH | 1 |
| Chen, YC | 1 |
| Tsao, CW | 1 |
| Yang, SS | 1 |
| Husted, SE | 2 |
| Lagerqvist, B | 6 |
| Kontny, F | 9 |
| Ståhle, E | 4 |
| Möller, BH | 1 |
| Scheinowitz, M | 1 |
| Heled, Y | 1 |
| Chouraqui, P | 1 |
| Vered, Z | 1 |
| Hayardeni, Y | 1 |
| Kotlyar, A | 1 |
| Castel, D | 1 |
| Livschitz, S | 1 |
| Barak, V | 1 |
| Savion, N | 1 |
| Eldar, M | 1 |
| Bergstrand, L | 2 |
| Fellenius, C | 1 |
| Lins, LE | 1 |
| Nilsson, T | 3 |
| Pehrsson, K | 2 |
| Siegbahn, A | 6 |
| SUSSMAN, I | 2 |
| LYDECKER, E | 1 |
| Manoharan, G | 1 |
| Norhammar, A | 1 |
| Malmberg, K | 1 |
| Diderholm, E | 2 |
| Rydén, L | 1 |
| Johanson, P | 1 |
| Paparella, S | 1 |
| Jacobsen, MD | 1 |
| Wagner, GS | 2 |
| Holmvang, L | 2 |
| Husted, S | 5 |
| Steffensen, R | 1 |
| Clemmensen, P | 2 |
| Lindbäck, J | 1 |
| Jernberg, T | 2 |
| Johnston, N | 1 |
| Stridsberg, M | 1 |
| Venge, P | 3 |
| Dudek, D | 1 |
| Chyrchel, M | 1 |
| Legutko, J | 1 |
| Bartuś, S | 1 |
| Rzeszutko, L | 1 |
| Dubiel, JS | 1 |
| Ripa, RS | 1 |
| Maynard, C | 1 |
| Sejersten, M | 1 |
| Grande, P | 1 |
| Mälarstig, A | 1 |
| Kim, W | 2 |
| Hwang, SH | 1 |
| Kim, KH | 1 |
| Hong, YJ | 1 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Nahrendorf, M | 1 |
| Aikawa, E | 1 |
| Figueiredo, JL | 1 |
| Stangenberg, L | 1 |
| van den Borne, SW | 1 |
| Blankesteijn, WM | 1 |
| Sosnovik, DE | 1 |
| Jaffer, FA | 1 |
| Tung, CH | 1 |
| Weissleder, R | 1 |
| Varda-Bloom, N | 1 |
| Blumberg, N | 1 |
| Ohad, D | 1 |
| Kher, A | 2 |
| Samama, MM | 1 |
| Buchwald, A | 2 |
| Hillis, SE | 1 |
| Monrad, S | 2 |
| Sanz, G | 2 |
| van der Meer, J | 2 |
| Olaisson, E | 2 |
| Undeland, S | 2 |
| Ludwig, K | 2 |
| Hillis, WS | 1 |
| Dale, J | 1 |
| Abildgaard, U | 3 |
| Pedersen, TR | 1 |
| Ernofsson, M | 1 |
| Strekerud, F | 1 |
| Toss, H | 3 |
| Gnarpe, J | 1 |
| Gnarpe, H | 1 |
| Frostfeldt, G | 2 |
| Ahlberg, G | 1 |
| Gustafsson, G | 1 |
| Helmius, G | 1 |
| Nygren, A | 1 |
| Dempfle, CE | 1 |
| Arnheim, K | 1 |
| Morais, J | 1 |
| Frostick, SP | 1 |
| Dellborg, DM | 1 |
| Chesebro, JH | 1 |
| Camm, AJ | 1 |
| Pineo, GF | 1 |
| Andrén, B | 1 |
| Genberg, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623] | Phase 3 | 1,899 participants (Actual) | Interventional | 2008-03-01 | Completed | ||
| STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction[NCT02777580] | Phase 4 | 609 participants (Actual) | Interventional | 2017-08-01 | Active, not recruiting | ||
| Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI). Randomized Clinical Trial[NCT04717986] | 188 participants (Actual) | Interventional | 2021-01-26 | Completed | |||
| Reperfusion Strategies in ST Elevation Myocardial Infarction Network - Sao Paulo Registry.[NCT02090712] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2010-01-31 | Enrolling by invitation | |||
| French Registry of Acute Coronary Syndrome With or Without ST Elevation 2010[NCT01237418] | 3,700 participants (Anticipated) | Observational | 2010-10-31 | Active, not recruiting | |||
| International Survey of Acute Coronary Syndromes in Transitional Countries[NCT01218776] | 36,000 participants (Anticipated) | Observational | 2010-09-28 | Recruiting | |||
| The Association Between Plasma DPP4 Activity And Prognosis of Patients With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention[NCT03046576] | 625 participants (Actual) | Observational | 2013-01-01 | Completed | |||
| An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Per[NCT00077844] | Phase 2/Phase 3 | 3,532 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| A Randomized, Double-Blind, Double-Dummy , Parallel Group, Multinational, Clinical Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With Acute ST-Segment Elevation Myocardial Infarction Receiving Fibrinolyt[NCT00077792] | Phase 3 | 20,506 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Multicenter Open Label Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase (Actilyse) in Patients With Acute Ischemic Stroke[NCT03151993] | Phase 3 | 336 participants (Actual) | Interventional | 2017-03-18 | Completed | ||
| Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients[NCT02301910] | Phase 3 | 392 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)[NCT00043784] | Phase 3 | 8,000 participants | Interventional | 2001-08-31 | Completed | ||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| Acute STEMI Treated With Primary Angioplasty and Intravenous 0.5 mg/kg Lovenox or UFH to Lower Ischemic and Bleeding Events[NCT00718471] | Phase 3 | 910 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction- The TRANSFER-AMI Trial[NCT00164190] | 1,200 participants (Anticipated) | Interventional | 2004-07-31 | Completed | |||
| Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667] | 43 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| Pharmacodynamics Study of Enoxalow, Produced by Blau Farmacêutica S/A, Compared to Clexane, Produced by Sanofi-Aventis Farmacêutica Ltda, in Healthy Subjects After Intravenous Administration.[NCT01692171] | Phase 1 | 32 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Percutaneous Revascularization in Infarction With Late Presentation and Absence of Viability: Effects on Left Ventricular Remodeling and Contractility[NCT05160311] | 70 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | |||
| A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention [NCT00046228] | Phase 3 | 2,461 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism[NCT02977013] | 42 participants (Actual) | Observational | 2013-08-31 | Completed | |||
| Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin[NCT00842374] | 32 participants (Actual) | Observational | 2008-12-31 | Completed | |||
| Impact of Residual Syntax Score and Syntax Revascularization Index on Outcomes of Acute Coronary Syndrome Patients With Multi-Vessel Disease[NCT03138473] | 149 participants (Actual) | Observational | 2018-07-01 | Completed | |||
| An International Randomised Trial of Early Versus Delayed Invasive Strategies in Patients With Non-ST Segment Elevation Acute Coronary Syndromes[NCT00552513] | 3,031 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes[NCT00139815] | Phase 3 | 20,078 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Very Early Initiation of Treatment With Thrombolysis and Low Molecular Weight Heparin, Versus Abciximab and Low Molecular Weight Heparin Followed by Percutaneous Coronary Intervention, for Acute ST-Elevation Myocardial Infarction[NCT00806403] | Phase 4 | 205 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| An Investigation of Activated Factor XII (Fxlla) as a Prognostic Marker.[NCT00521976] | 871 participants (Actual) | Observational | 2002-11-30 | Completed | |||
| Which Early ST Elevation Myocardial Infarction Therapy? The WEST Study[NCT00121446] | Phase 2/Phase 3 | 300 participants | Interventional | 2003-07-31 | Completed | ||
| Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| Randomized Investigation of Chest Pain Diagnostic Strategies[NCT01035047] | 105 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Randomized Cost Comparison of Cardiac MRI Use in ED Patients With Chest Pain[NCT00678639] | 110 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| Improving Early Risk Stratification in Patients Presenting to Emergency Departments With Undifferentiated Chest Pain[NCT02364271] | 602 participants (Actual) | Observational | 2013-03-31 | Completed | |||
| A Randomized Cost Minimization Analysis Comparing Same Day Discharge With Overnight Hospital Stay Following Elective and Low Risk Urgent Percutaneous Coronary Intervention.[NCT02207270] | 4 participants (Actual) | Interventional | 2014-08-11 | Terminated (stopped due to Unable to meet projected enrollment) | |||
| Serum Oxidative Status as a Potential Predictor of Coronary Artery Disease.[NCT03646019] | 200 participants (Anticipated) | Observational | 2018-09-30 | Not yet recruiting | |||
| Prevalence of the Appearance of Diabetic Ulcers, After the Manufacture and Adaptation of Personalized Insoles, With Monitoring of Temperature and Plantar Pressure in Diabetic Patients[NCT05843929] | 86 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin[NCT01931852] | 312 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| Acute Angioplasty (Primary PCI) Versus Traditional Early Invasive Treatment of Patients Presenting With NSTEMI (The Second Danish Non-ST-Elevation MI Trial - DaNSTEMI-2)[NCT00493584] | 14 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Due to insufficient patient inclusion the study has been stopped prematurely.) | |||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| A Clinical Trial of Conservative Versus Routine Invasive Management in Patients With Prior Coronary Artery Bypass Surgery in Patients With a Non-ST Elevation Acute Coronary Syndrome: a Pilot Trial and Registry.[NCT01895751] | Phase 4 | 60 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 50 |
| Primary PCI (Group B) | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 59 |
| Primary PCI (Group B) | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 100 |
| Primary PCI (Group B) | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 117 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 77 |
| Primary PCI (Group B) | 85 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 43 |
| Primary PCI (Group B) | 42 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 116 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 31 |
| Primary PCI (Group B) | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 41 |
| Primary PCI (Group B) | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 57 |
| Primary PCI (Group B) | 72 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 9 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 6 |
| Primary PCI (Group B) | 3 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 61 |
| Primary PCI (Group B) | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 206 |
| Primary PCI (Group B) | 191 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 23 |
| Primary PCI (Group B) | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 45 |
| Primary PCI (Group B) | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 19 |
| Primary PCI (Group B) | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 1 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 32 |
| Primary PCI (Group B) | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 10 |
| Primary PCI (Group B) | 29 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 2 |
| Primary PCI (Group B) | 0 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 7 |
| Primary PCI (Group B) | 4 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 8 |
| Primary PCI (Group B) | 1 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 267 |
| Primary PCI (Group B) | 236 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 15 |
| Primary PCI (Group B) | 5 |
All-cause mortality through 1 year from randomization. (NCT00046228)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 56 |
| Abciximab Facilitated PCI Group | 60 |
| Reteplase/Abciximab Facilitated PCI Group | 52 |
All cause mortality occurred through 90 days from randomization. (NCT00046228)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 36 |
| Abciximab Facilitated PCI Group | 45 |
| Reteplase/Abciximab Facilitated PCI Group | 43 |
The complications of myocardial infarction (MI) is defined as any event of rehospitalization or emergency department visit for CHF, cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization. (NCT00046228)
Timeframe: 90 Days
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 72 |
| Abciximab Facilitated PCI Group | 61 |
| Reteplase/Abciximab Facilitated PCI Group | 61 |
(NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 139 |
| Abciximab Facilitated PCI Group | 178 |
| Reteplase/Abciximab Facilitated PCI Group | 271 |
All cases of cerebrovascular event were confirmed by a CEC (Clinical Endpoints Committee). (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 1 |
| Abciximab Facilitated PCI Group | 0 |
| Reteplase/Abciximab Facilitated PCI Group | 5 |
Subjects with nonintracranial TIMI bleeding (either major or minor) through discharge/day 7, originating from vascular instrumentation sites, non-instrument related bleeding, as well as overall, were examined. (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participant (Number) |
|---|---|
| Primary PCI Group | 55 |
| Abciximab Facilitated PCI Group | 81 |
| Reteplase/Abciximab Facilitated PCI Group | 118 |
Number of subjects with one or more of the following: 2nd or 3rd Degree AVB, Asystole, Sustained V Tach, A Fib/Flutter, EMD/Pulseless Electrical Activity, Heart Failure, Tamponade, Myocardial Rupture, Papillary Muscle Rupture, Ventricular Septal Defect, Pulmonary Embolism, Systemic Arterial Embolism and/or Pericarditis/Pericardial Effusion. (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 128 |
| Abciximab Facilitated PCI Group | 122 |
| Reteplase/Abciximab Facilitated PCI Group | 120 |
Severe thrombocytopenia is defined as platelet count < 50,000 cells/μL. (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 11 |
| Abciximab Facilitated PCI Group | 16 |
| Reteplase/Abciximab Facilitated PCI Group | 16 |
(NCT00046228)
Timeframe: 60 to 90 minutes
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 75 |
| Abciximab Facilitated PCI Group | 85 |
| Reteplase/Abciximab Facilitated PCI Group | 108 |
Occurs within 90 days and is composite of all-cause mortality or complications of myocardial infarction (MI) (rehospitalization or emergency department visit for congestive heart failure (CHF), cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization). (NCT00046228)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 86 |
| Abciximab Facilitated PCI Group | 86 |
| Reteplase/Abciximab Facilitated PCI Group | 81 |
(NCT00552513)
Timeframe: 180 days
| Intervention | Eparticipants (Number) |
|---|---|
| Early Intervention | 264 |
| Delayed Intervention | 280 |
(NCT00552513)
Timeframe: 180 days
| Intervention | participants (Number) |
|---|---|
| Early Intervention | 153 |
| Delayed Intervention | 163 |
(NCT00552513)
Timeframe: 180 days
| Intervention | participants (Number) |
|---|---|
| Early Intervention | 151 |
| Delayed Intervention | 186 |
(NCT00806403)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Thrombolysis | 4 |
| Invasive | 3 |
ST-segment elevation resolution was measured in the lead with most prominent ST elevation at time of inclusion (NCT00806403)
Timeframe: 120 minutes after inclusion
| Intervention | participants (Number) |
|---|---|
| Thrombolysis | 47 |
| Invasive | 51 |
Thrombolysis In Myocardial Infarction (TIMI) flow grade in the infarct related artery 5-7 days after inclusion. (NCT00806403)
Timeframe: 5-7 days after inclusion
| Intervention | participants (Number) |
|---|---|
| Thrombolysis | 35 |
| Invasive | 56 |
(NCT00806403)
Timeframe: 30 days
| Intervention | Participants (Number) |
|---|---|
| Thrombolysis | 2 |
| Invasive | 0 |
(NCT00806403)
Timeframe: 30 days
| Intervention | Participants (Number) |
|---|---|
| Thrombolysis | 3 |
| Invasive | 0 |
Recurrent Troponin-T (TnT) positive events; Symptoms of coronary ischemia associated with TnT >0.05 ng/mL with a pattern of gradual rise and fall in TnT (NCT00521976)
Timeframe: 24 months.
| Intervention | Participants (Number) |
|---|---|
| Group 1 | 155 |
(NCT00521976)
Timeframe: 24 months.
| Intervention | Participants. (Number) |
|---|---|
| Group 1 | 138 |
(NCT01035047)
Timeframe: Index Hospitalization discharge through 90 days
| Intervention | participants (Number) |
|---|---|
| CDU-CMR Protocol | 0 |
| Inpatient Care | 3 |
(NCT01035047)
Timeframe: Duration of Index Hospitalization, an average of 1-2 days
| Intervention | hours (Median) |
|---|---|
| CDU-CMR Protocol | 21.1 |
| Inpatient Care | 26.3 |
(NCT01035047)
Timeframe: Index Hospitalization through 90 days
| Intervention | participants (Number) |
|---|---|
| CDU-CMR Protocol | 0 |
| Inpatient Care | 0 |
(NCT01035047)
Timeframe: Index Hospitalization through 90 days
| Intervention | participants (Number) |
|---|---|
| CDU-CMR Protocol | 1 |
| Inpatient Care | 0 |
(NCT01035047)
Timeframe: Index Hospitalization through 90 days
| Intervention | participants (Number) |
|---|---|
| CDU-CMR Protocol | 7 |
| Inpatient Care | 20 |
Any event leading to early termination of the MRI acquisition, or requiring intervention by a physician, will be considered an adverse event related to MRI, excluding physician termination of image acquisition due to concerns of cardiac ischemia. (NCT00678639)
Timeframe: Occuring in the MRI scanning suite or within 30 minutes of the last image acquisition.
| Intervention | Participants (Number) |
|---|---|
| Emergency Department (ED) Observation Unit | 3 |
| Usual Care | 1 |
Participants with ACS and admitted or not experiencing ACS and discharged will be considered a correct admission decision. Remaining participants will be considered to have incorrect admission decisions. (NCT00678639)
Timeframe: 30 Days
| Intervention | Participants (Number) |
|---|---|
| Emergency Department (ED) Observation Unit | 43 |
| Usual Care | 6 |
Index hospitalization refers to the hospital visit during which the participant was enrolled in the trial. The primary outcome is examining the cost for this visit. (NCT00678639)
Timeframe: Emergency Department (ED) arrival through hospital discharge, median length of stay was 28.1 hours
| Intervention | US Dollars (Median) |
|---|---|
| Emergency Department (ED) Observation Unit | 2062 |
| Usual Care | 2680 |
The number of participants able to complete the planned imaging sequences will be measured. (NCT00678639)
Timeframe: Emergency Department (ED) arrival through hospital discharge
| Intervention | Participants (Number) |
|---|---|
| Emergency Department (ED) Observation Unit | 46 |
Measured as self report, assessed during telephone follow-up. (NCT00678639)
Timeframe: 30d, 3mo, 6mo, and 1 year
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Cardiac related office visit | Cardiac related ED visit | Cardiac related hospitalization | Cardiac related procedures | Cardiac Catheterization | Stress Test | Resting Echocardiogram | |
| Emergency Department (ED) Observation Unit | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Usual Care | 4 | 4 | 3 | 4 | 3 | 1 | 1 |
Outcome is the number of patients with effecacy MACE within 30 days after initial ED presentation. Effecacy MACE consists of revascularization (e.g.coronary artery bypass grafting),ventricular arrhythmia needing intervention and high-degree atrioventricular block needing intervention. (NCT02364271)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Not Low Risk Group | 26 |
| Low Risk Group | 0 |
Outcome is the number of patients with safety MACE within 30 days after initial ED presentation. Safety MACE is defined as relating to safety outcome,which consists of all-cause mortality (included cardiac death),cardiac arrest,readmission with myocardial infarction and cardiogenic shock (NCT02364271)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Not Low Risk Group | 31 |
| Low Risk Group | 0 |
74 reviews available for dalteparin and Myocardial Infarction
| Article | Year |
|---|---|
Low-molecular-weight heparins in the management of acute coronary syndromes.
Topics: Angina, Unstable; Canada; Coronary Disease; Dalteparin; Enoxaparin; Fibrinolytic Agents; Hemorrhage; | 1999 |
Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
Topics: Aged; Angina, Unstable; Anticoagulants; Dalteparin; Double-Blind Method; Electrocardiography; Enoxap | 1999 |
Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Dalteparin; Enoxaparin; H | 2000 |
[Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Confidence Intervals; Daltepari | 2000 |
[Low molecular weight heparins in acute coronary syndrome].
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; En | 2001 |
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin; | 2001 |
[Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
Topics: Acute Disease; Anticoagulants; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Daltepar | 2001 |
The role of low-molecular-weight heparin in the management of acute coronary syndromes.
Topics: Anticoagulants; Cardiac Catheterization; Combined Modality Therapy; Dalteparin; Double-Blind Method; | 2001 |
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution | 2013 |
Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brain Ischemi | 2015 |
Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; American Heart Association; Angina, Unstable; Anticoagulants; Clinical Tria | 2017 |
Use of anticoagulants in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: a potential role for enoxaparin.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Electrocardiography; Enoxaparin; Female; Humans; Mal | 2008 |
Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Humans; Myocar | 2009 |
Safety evaluation of enoxaparin in currently approved indications.
Topics: Adult; Animals; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Myocardial Infarction; Posto | 2009 |
Use of low-molecular-weight heparins during percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Cardiac Catheteriz | 2011 |
Antithrombotic therapy in ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Electrocardiography; Enoxaparin | 2011 |
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Hep | 2012 |
Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Coronary Art | 2003 |
The role of low-molecular-weight heparin in the management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Coagulation F | 2003 |
Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction.
Topics: Aged; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolysis; Fibrinolytic | 2003 |
Enoxaparin for the treatment of acute myocardial infarction with persistent ST-segment elevation.
Topics: Anticoagulants; Clinical Trials as Topic; Electrocardiography; Enoxaparin; Humans; Myocardial Infarc | 2003 |
Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Coronary | 2003 |
Anticoagulation with low-molecular-weight heparin in patients with heart diseases.
Topics: Anticoagulants; Atrial Fibrillation; Dalteparin; Enoxaparin; Heart Diseases; Heparin, Low-Molecular- | 2004 |
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
Topics: Angina Pectoris; Angina, Unstable; Cause of Death; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Hepa | 2004 |
A marriage of enhancement: fibrinolysis and conjunctive therapy.
Topics: Animals; Antithrombins; Aspirin; Blood Platelets; Cell Adhesion; Clinical Trials as Topic; Dose-Resp | 2004 |
Current role of antithrombotic agents in the treatment of acute coronary syndromes.
Topics: Aged; Anticoagulants; Arginine; Blood Platelets; Clinical Trials as Topic; Enoxaparin; Fibrinolytic | 2004 |
Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Myoc | 2005 |
Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.
Topics: Area Under Curve; Drug Therapy, Combination; Emergency Treatment; Enoxaparin; Fibrinolytic Agents; H | 2006 |
Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.
Topics: Anticoagulants; Dalteparin; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; | 2007 |
Enoxaparin in acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Enoxaparin; Humans; Myocardial Infarctio | 2007 |
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.
Topics: Acute Coronary Syndrome; Antithrombins; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; | 2007 |
New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction.
Topics: Angina, Unstable; Anticoagulants; Electrocardiography; Enoxaparin; Fondaparinux; Heart Conduction Sy | 2007 |
Efficacy and safety of fondaparinux in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxa | 2007 |
Utilizing enoxaparin in the management of STEMI.
Topics: Clinical Trials as Topic; Enoxaparin; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibi | 2007 |
Management of ST-segment elevation myocardial infarction in EDs.
Topics: Abciximab; Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anti | 2008 |
Enoxaparin: a review of its use in ST-segment elevation myocardial infarction.
Topics: Adult; Aged; Anticoagulants; Coronary Angiography; Electrocardiography; Enoxaparin; Female; Humans; | 2008 |
Factor Xa inactivation in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Fondapa | 2008 |
Contemporary use of and future roles for heparin in antithrombotic therapy.
Topics: Anticoagulants; Antithrombins; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; | 1995 |
TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction
Topics: Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Double-Blind Method; Enoxapar | 1998 |
Enoxaparin. A review of its clinical potential in the management of coronary artery disease.
Topics: Angina, Unstable; Angioplasty; Coronary Disease; Drug Tolerance; Enoxaparin; Fibrinolytic Agents; Hu | 1998 |
[Enoxaparin: molecular structure aspects, pharmacokinetics, efficiency in internal medicine].
Topics: Adult; Enoxaparin; Fibrinolytic Agents; Humans; Myocardial Infarction; Thrombosis | 1998 |
Anticoagulants in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease | 1999 |
Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
Topics: Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Dalteparin; Death, Sudden, Cardiac; Enox | 1999 |
[Enoxaparin in the treatment of acute myocardial infarction].
Topics: Animals; Blood Coagulation; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Humans; Myocardial | 1999 |
Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Enoxaparin; F | 2000 |
Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?
Topics: Acetates; Angina, Unstable; Anticoagulants; Confidence Intervals; Controlled Clinical Trials as Topi | 2000 |
Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Heparin, Low-Molecular | 2000 |
Low molecular weight heparin in acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty; Dalteparin; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-W | 1999 |
Low molecular weight heparins and coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Heparin, Low-Molecular-Weight; Human | 2000 |
Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction.
Topics: Aged; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Middle Aged; Myocardial Infarction; Treatmen | 2000 |
Management of venous and cardiovascular thrombosis: enoxaparin.
Topics: Angina, Unstable; Anticoagulants; Coronary Thrombosis; Enoxaparin; Fibrinolytic Agents; Humans; Myoc | 2000 |
Redefining medical treatment in the management of unstable angina.
Topics: Abciximab; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Diagn | 2000 |
Deep venous thrombosis prophylaxis in patients with heart disease.
Topics: Angina, Unstable; Anticoagulants; Critical Care; Enoxaparin; Heart Failure; Heparin; Humans; Myocard | 2001 |
The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Electroca | 2001 |
Prophylaxis of venous thromboembolism in medical patients.
Topics: Anticoagulants; Bandages; Brain Ischemia; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Myocard | 2001 |
Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Fibrinolytic Agents; Humans; My | 2001 |
[Antithrombotic treatment protocols in interventional cardiology].
Topics: Aspirin; Clopidogrel; Drug Resistance; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial | 2001 |
Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.
Topics: Angina, Unstable; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial | 2002 |
Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups.
Topics: Adult; Aged; Angina, Unstable; Clinical Trials, Phase III as Topic; Electrocardiography; Enoxaparin; | 2001 |
Glycoprotein IIb/IIIa combination therapy in acute myocardial infarction: tailoring therapies to optimize outcome.
Topics: Abciximab; Algorithms; Antibodies, Monoclonal; Drug Therapy, Combination; Enoxaparin; Humans; Immuno | 2002 |
Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control.
Topics: Anticoagulants; Aspirin; Confidence Intervals; Coronary Artery Disease; Coronary Thrombosis; Drug Th | 2002 |
Reviparin sodium clivarine: a review of its therapeutic use.
Topics: Anticoagulants; Coronary Disease; Coronary Restenosis; Heparin, Low-Molecular-Weight; Humans; Myocar | 2004 |
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic | 2002 |
Thrombolytic therapy: no room for error.
Topics: Angina, Unstable; Dalteparin; Emergency Nursing; Fatal Outcome; Fibrinolytic Agents; Humans; Male; M | 2004 |
Biochemical markers of myocardial damage for early diagnosis and prognosis in patients with acute coronary syndromes. Minireview based on a doctorial thesis.
Topics: Aged; Angina, Unstable; Anticoagulants; Biomarkers; Cohort Studies; Creatine Kinase; Dalteparin; End | 1996 |
[Low molecular weight heparin in unstable angina].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Drug; Drug Therap | 1996 |
Targeting treatment for optimal outcome.
Topics: Age Factors; Aged; Angina, Unstable; Anticoagulants; Aspirin; Biomarkers; Clinical Protocols; Daltep | 2000 |
[Long-term administration of Dalteparin in unstable coronary syndrome. FRISC II study opens novel therapeutic perspectives. Fragmin and Fast Revascularization during Instability in Coronary Artery Disease].
Topics: Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; Death, Sudden, Ca | 2000 |
Implications of the FRISCII trial: initial medical stabilization followed by an early invasive approach is the preferred strategy in unstable coronary syndromes.
Topics: Angina, Unstable; Dalteparin; Electrocardiography; Fibrinolytic Agents; Humans; Injections, Intraven | 2000 |
Prognostic value of cardiac troponins in patients with acute coronary disease.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Dalteparin; Female; Fibrinolytic Agents | 2000 |
Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
Topics: Angina, Unstable; Dalteparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial | 2000 |
Death after joint replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; | 2000 |
Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
Topics: Algorithms; Angina, Unstable; Anticoagulants; Biomarkers; Combined Modality Therapy; Coronary Angiog | 2000 |
Dalteparin sodium.
Topics: Animals; Anticoagulants; Clinical Trials as Topic; Dalteparin; Humans; Myocardial Infarction; Venous | 2001 |
156 trials available for dalteparin and Myocardial Infarction
| Article | Year |
|---|---|
Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Female; Fibrinolytic Agents; Hemorrhage; Hum | 2003 |
[Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antithrombins; Female; Heparin; Huma | 2005 |
A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study.
Topics: Adult; Aged; Angina, Unstable; Cost-Benefit Analysis; Dalteparin; Disease-Free Survival; Drug Admini | 2006 |
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male | 1996 |
[Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Female; Heparin; Humans; Male; Mid | 1998 |
Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
Topics: Aged; Angina, Unstable; Anticoagulants; Dalteparin; Double-Blind Method; Electrocardiography; Enoxap | 1999 |
Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischa
Topics: Adult; Angina, Unstable; Anticoagulants; Double-Blind Method; Female; Humans; Male; Myocardial Infar | 1999 |
[Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction].
Topics: Aged; Electrocardiography; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged | 2004 |
Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Coagulation; Drug Administration Schedule; Drug Therapy, Combination; Electroca | 2006 |
Effects of two dosages of subcutaneous low molecular weight heparin (Parnaparin) and of unfractionated heparin on fibrin formation and lipolysis in acute myocardial infarction.
Topics: Aged; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Fibrin; Heparin; Heparin, Low- | 1992 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).
Topics: Aged; Anticoagulants; Austria; Cause of Death; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2013 |
Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; France; Heart Conduction System; Hemorrhage; | 2015 |
Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty a
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Electrocardiography; | 2015 |
Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction.
Topics: Aged; Clopidogrel; Comparative Effectiveness Research; Electrocardiography; Enoxaparin; Female; Huma | 2016 |
Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the Randomized ATOLL Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Hepari | 2017 |
[Betrixaban reduces tromboembolic events].
Topics: Administration, Oral; Benzamides; Causality; Comorbidity; Enoxaparin; Fibrinolytic Agents; Humans; M | 2016 |
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Antithrombins; Dose-Response Relationship, Drug; | 2008 |
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Humans; | 2009 |
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Double-Blind Method; | 2008 |
Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Coronary Artery Disease; Coronary Thromb | 2009 |
Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Drug Therapy, Combination; Endpoint Det | 2009 |
Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
Topics: Aged; Aged, 80 and over; Cost-Benefit Analysis; Double-Blind Method; Enoxaparin; Female; Fibrinolyti | 2009 |
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Australia; Canada; Enoxaparin; Europe; Female; | 2009 |
Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction
Topics: Aged; Anticoagulants; Canada; Cost-Benefit Analysis; Double-Blind Method; Enoxaparin; Female; Fibrin | 2009 |
Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Drug-Related Side Effects and Adverse Reaction | 2010 |
Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Drug Therapy, Combination; Drug-Eluting Stents | 2010 |
One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial.
Topics: Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents | 2010 |
Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Topics: Aged; Cause of Death; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Elec | 2010 |
Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registry.
Topics: Anticoagulants; Cause of Death; Dose-Response Relationship, Drug; Enoxaparin; Female; Follow-Up Stud | 2010 |
The impact of postrandomization crossover of therapy in acute coronary syndromes care.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cross-Over Studies; Enoxaparin; Female; Hemorrhage; H | 2011 |
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Electrocardiography; Enoxaparin; Female; Fibri | 2011 |
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Electrocardiography; Enoxaparin; Female; Fibri | 2011 |
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Electrocardiography; Enoxaparin; Female; Fibri | 2011 |
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Electrocardiography; Enoxaparin; Female; Fibri | 2011 |
Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Canada; Dose-Response Relationship, Drug; Electrocardiography; | 2012 |
Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase.
Topics: Aged; Angioplasty, Balloon, Coronary; Dose-Response Relationship, Drug; Enoxaparin; Female; Fibrinol | 2012 |
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.
Topics: Aged; Biomarkers; Creatine Kinase, MB Form; Enoxaparin; Female; Follow-Up Studies; Humans; Male; Mid | 2012 |
Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study.
Topics: Adult; Aged; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents | 2002 |
Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; Electro | 2002 |
Comparison of two needle sizes for subcutaneous administration of enoxaparin: effects on size of hematomas and pain on injection.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Enoxaparin; Female; Hematoma; Huma | 2002 |
Head-to-head comparison of two different low-molecular-weight heparins in acute coronary syndrome: a single center experience.
Topics: Aged; Angina, Unstable; Anticoagulants; Dalteparin; Enoxaparin; Female; Heparin, Low-Molecular-Weigh | 2002 |
Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction.
Topics: Aged; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolysis; Fibrinolytic | 2003 |
Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
Topics: Angina, Unstable; Anticoagulants; Biomarkers; Blood Platelets; Dalteparin; Enoxaparin; Female; Hepar | 2003 |
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem | 2003 |
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem | 2003 |
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem | 2003 |
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem | 2003 |
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial.
Topics: Aged; Angina, Unstable; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Huma | 2003 |
The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes.
Topics: Aged; Angina, Unstable; Anticoagulants; Blood Coagulation; Enoxaparin; Factor Xa; Female; Humans; In | 2003 |
ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction.
Topics: Abciximab; Antibodies, Monoclonal; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Hum | 2003 |
Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Angina, Unstable; Anticoagulants; Cohort Studies; Enoxaparin; Factor Xa Inhibitors; Female; Half-Lif | 2003 |
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
Topics: Abciximab; Alberta; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Belgium; | 2003 |
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
Topics: Administration, Oral; Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; | 2003 |
Optimizing outcomes in ST-segment elevation myocardial infarction.
Topics: Drug Therapy, Combination; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; My | 2003 |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 2003 |
Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial.
Topics: Age Factors; Aged; Anticoagulants; Bundle-Branch Block; Double-Blind Method; Drug Therapy, Combinati | 2003 |
Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel
Topics: Aged; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fem | 2004 |
Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial infarction.
Topics: Aged; Drug Therapy, Combination; Enoxaparin; Female; Heparin; Humans; Hypotension; Male; Middle Aged | 2003 |
Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Mo | 2004 |
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
Topics: Abciximab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Aspirin; Drug Administration Schedule; D | 2004 |
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans | 2004 |
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Enoxaparin; Female; Fibrinolytic Agents; Hemo | 2004 |
Accelerated streptokinase and enoxaparin in ST-segment elevation acute myocardial infarction (the ASENOX study).
Topics: Adult; Aged; Drug Administration Schedule; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Hea | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
Topics: Angina, Unstable; Anticoagulants; Coronary Angiography; Electrocardiography; Enoxaparin; Heparin; Hu | 2004 |
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Cardiac Catheteriza | 2004 |
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Cardiac Catheteriza | 2004 |
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Cardiac Catheteriza | 2004 |
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Cardiac Catheteriza | 2004 |
Double bolus of 0.75 MU streptokinase plus enoxaparin versus front-loaded alteplase plus unfractionated heparin in ST-segment elevation myocardial infarction.
Topics: Aged; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Mid | 2003 |
Streptokinase and enoxaparin in the pre-hospital management of the ST-segment elevation acute myocardial infarction.
Topics: Adult; Aged; Emergency Medical Services; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Midd | 2002 |
Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.
Topics: Blood Flow Velocity; Coronary Circulation; Coronary Vessels; Enoxaparin; Female; Fibrinolytic Agents | 2005 |
Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial.
Topics: Age Factors; Blood Pressure; Diagnosis, Differential; Drug Therapy, Combination; Emergency Medical S | 2005 |
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months.
Topics: Acute Disease; Aged; Angina, Unstable; Electrocardiography; Enoxaparin; Female; Follow-Up Studies; H | 2005 |
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
Topics: Enoxaparin; Fibrinolytic Agents; Follow-Up Studies; Heparin; Humans; Mortality; Myocardial Infarctio | 2005 |
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Coronary Disease; Double-Blind Method; Enoxap | 2005 |
[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome].
Topics: Anticoagulants; Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolysis; Fibrinolytic Ag | 2005 |
Using a clinical pathway and education to reduce inappropriate prescribing of enoxaparin in patients with acute coronary syndromes: a controlled study.
Topics: Angina, Unstable; Anticoagulants; Critical Pathways; Drug Utilization; Enoxaparin; Female; Hospitals | 2006 |
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin
Topics: Angina, Unstable; Anticoagulants; Aspirin; Enoxaparin; Eptifibatide; Female; Heparin; Humans; Male; | 2006 |
Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose.
Topics: Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic | 2006 |
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Fondapar | 2006 |
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
Topics: Aged; Anticoagulants; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolyt | 2006 |
Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infa
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Antifibrinolytic Age | 2006 |
A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug | 2006 |
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Drug Therapy, Combin | 2006 |
Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Enoxaparin; F | 2006 |
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
Topics: Aged; Coronary Artery Disease; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middl | 2006 |
Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: the TRANSFER-AMI pilot feasibility study.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Coronary Angiogra | 2006 |
Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): study rationale and design.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Administration Sch | 2007 |
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Transfusion; Chi-Square Distribution; Coronary Angiograp | 2007 |
Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome.
Topics: Anticoagulants; Electrocardiography, Ambulatory; Enoxaparin; Female; Follow-Up Studies; Heparin; Hum | 2007 |
A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Canada; Clopidogrel; Corona | 2007 |
Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25.
Topics: Adult; Age Factors; Death, Sudden, Cardiac; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hep | 2007 |
Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Antifibrinolytic Agents; Coronary Artery Bypass; Double-Blind Method | 2007 |
Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Chemotherapy, Adjuvant; Contraindications; Double-Blind Method | 2007 |
The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial.
Topics: Aged; Aged, 80 and over; Creatinine; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; H | 2007 |
Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Topics: Aged; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic | 2007 |
Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
Topics: Aged; Decision Making; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; | 2007 |
Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial.
Topics: Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Multivariate Analysis; Myocardia | 2007 |
Does coronary angioplasty after timely thrombolysis improve microvascular perfusion and left ventricular function after acute myocardial infarction?
Topics: Angioplasty, Balloon; Cineangiography; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle | 2007 |
A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study.
Topics: Aged; Antithrombins; Death, Sudden, Cardiac; Drug Therapy, Combination; Electrocardiography; Enoxapa | 2007 |
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Coronary Disease; Death, Sudden, Cardiac; | 2007 |
ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis.
Topics: Adult; Age Factors; Aged; Clopidogrel; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; | 2007 |
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cohort Studies; Double-Blind Metho | 2007 |
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRAC
Topics: Aged; Aspirin; Diabetes Complications; Drug Therapy, Combination; Electrocardiography; Enoxaparin; F | 2007 |
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Electrocardiography; Enoxaparin; | 2008 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxaparin; Factor Xa Inh | 2008 |
Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Enoxaparin; Female; Fibrinolytic Ag | 1996 |
Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators.
Topics: Aged; Angina, Unstable; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; M | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy.
Topics: Aged; Angina, Unstable; Biomarkers; Cause of Death; Enoxaparin; Female; Fibrinolytic Agents; Follow- | 1998 |
Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.
Topics: Aged; Angina, Unstable; Anticoagulants; C-Reactive Protein; Enoxaparin; Female; Fibrinogen; Heparin; | 1998 |
ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
Topics: Adult; Angina, Unstable; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low- | 1998 |
Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Coronary Disease; Drug Administra | 1999 |
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Creatine Kinase; Double-Blind Method; Electro | 1999 |
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
Topics: Angina, Unstable; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardi | 1999 |
Low-molecular-weight heparin alone versus a combination of unfractionated heparin and low-molecular-weight heparin.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Fema | 2000 |
Low-molecular-weight heparins in acute myocardial infarction: rationale and results of a pilot study.
Topics: Aspirin; Drug Administration Routes; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Hep | 2000 |
Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.
Topics: Aged; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Biomarkers; Blood Platelets; Daltepa | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
Topics: Aged; Angina, Unstable; Decision Making; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hepar | 2000 |
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
Topics: Adult; Aged; Angina, Unstable; Cardiac Catheterization; Double-Blind Method; Enoxaparin; Female; Fib | 2000 |
Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time.
Topics: Aged; Angina, Unstable; Double-Blind Method; Electrocardiography; Enoxaparin; Fibrinolytic Agents; H | 2000 |
Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy.
Topics: Aged; Angina, Unstable; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Stud | 2000 |
The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
Topics: Adult; Aged; Clinical Protocols; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; | 2000 |
Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; F | 2000 |
Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Double-Blind Method; Enoxaparin; Female; Heparin; Humans; | 2001 |
The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.
Topics: Anticoagulants; Drug Therapy, Combination; Enoxaparin; Humans; Hypolipidemic Agents; Myocardial Infa | 2001 |
Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Circulation; Enoxaparin; Female; Heparin; He | 2001 |
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Drug Therapy, Combination; Enoxapa | 2001 |
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Drug Therapy, Combination; Enoxapa | 2001 |
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Drug Therapy, Combination; Enoxapa | 2001 |
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Drug Therapy, Combination; Enoxapa | 2001 |
Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Antithrombin III; Biomarkers; Cardiovascular | 2001 |
Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
Topics: Aged; Angina, Unstable; Antifibrinolytic Agents; Double-Blind Method; Electrocardiography; Enoxapari | 2001 |
Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Blood Flow Velocity; Cohort Studies; Corona | 2002 |
Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
Topics: Aged; Anticoagulants; Endpoint Determination; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Hep | 2002 |
The SYNERGY trial: study design and rationale.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Fibrinol | 2002 |
Identification of patients at high risk for death and cardiac ischemic events after hospital discharge.
Topics: Angina, Unstable; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infar | 2002 |
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.
Topics: Aged; Angina Pectoris, Variant; Anticoagulants; Bundle-Branch Block; Double-Blind Method; Female; He | 2005 |
Comparison of tirofiban combined with dalteparin or unfractionated heparin in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Dalteparin; Female; Heparin; Humans; Male; Mid | 2011 |
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization.
Topics: Coronary Artery Disease; Dalteparin; Double-Blind Method; Female; Fibrinolytic Agents; Hemorrhage; H | 2002 |
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Topics: Abciximab; Administration, Cutaneous; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood F | 2003 |
Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
Topics: Aged; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Dalteparin; Diabetes Co | 2004 |
Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study population.
Topics: Aged; Coronary Artery Bypass; Dalteparin; Disease-Free Survival; Electrocardiography; Fibrinolytic A | 2005 |
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy.
Topics: Acute Disease; Aged; Angina, Unstable; Dalteparin; Electrocardiography; Female; Fibrinolytic Agents; | 2005 |
[Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine].
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dal | 2004 |
Consideration of the total ST-segment deviation on the initial electrocardiogram for predicting final acute posterior myocardial infarct size in patients with maximum ST-segment deviation as depression in leads V1 through V3. A FRISC II substudy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Dalteparin; Electrocardiography; Female; | 2005 |
Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Base Sequence; Biomarkers; CD40 Ligand; Coronary Dise | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Dalteparin; Female; Fibrinolytic Agents; Follo | 2006 |
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Daltepa | 1996 |
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation Tests; | 1997 |
Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Double-Blind | 1997 |
Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease.
Topics: Angina, Unstable; Anticoagulants; Dalteparin; Humans; Injections, Subcutaneous; Myocardial Infarctio | 1997 |
Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
Topics: Angina, Unstable; Anticoagulants; Coronary Angiography; Coronary Disease; Dalteparin; Drug Therapy, | 1997 |
Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study.
Topics: Aged; Anticoagulants; Dalteparin; Double-Blind Method; Embolism; Female; Heart Diseases; Heart Ventr | 1997 |
Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease.
Topics: Aged; Angina, Unstable; Dalteparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardi | 1998 |
Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease.
Topics: Adult; Angina, Unstable; Anticoagulants; Blood Coagulation; Coronary Disease; Dalteparin; Drug Admin | 1999 |
Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).
Topics: Adult; Aged; Biomarkers; Chemotherapy, Adjuvant; Coronary Angiography; Coronary Circulation; Daltepa | 1999 |
Fibrin monomer antigen: a novel marker of mortality in acute myocardial infarction.
Topics: Aged; Dalteparin; Double-Blind Method; Female; Fibrin; Fibrinolytic Agents; Humans; Immunoenzyme Tec | 1999 |
Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Cohort Studies; Dalteparin; Double-Blind Method; F | 1999 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
Topics: Angina, Unstable; Dalteparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial | 2000 |
Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
Topics: Algorithms; Angina, Unstable; Anticoagulants; Biomarkers; Combined Modality Therapy; Coronary Angiog | 2000 |
The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study.
Topics: Anticoagulants; Dalteparin; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Re | 2001 |
Improving outcomes in acute coronary syndromes--the FRISC II trial.
Topics: Adult; Angina, Unstable; Anticoagulants; Dalteparin; Female; Humans; Male; Myocardial Infarction; My | 2001 |
The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy.
Topics: Aged; Biomarkers; Cohort Studies; Confidence Intervals; Coronary Disease; Dalteparin; Electrocardiog | 2002 |
165 other studies available for dalteparin and Myocardial Infarction
| Article | Year |
|---|---|
Acute myocardial infarction in a patient with severe unrecognized mitral stenosis.
Topics: Analgesics; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Aspirin; Atrial Fibril | 2006 |
Low-molecular weight heparins.
Topics: Angina, Unstable; Animals; Anticoagulants; Antithrombins; Clinical Trials as Topic; Dalteparin; Enox | 1997 |
[Fraxiparin and prevention of left ventricular thrombosis in non-thrombolyzed myocardial infarction. FRATIV Study].
Topics: Aged; Drug Administration Schedule; Female; Heart Ventricles; Heparin, Low-Molecular-Weight; Humans; | 1997 |
Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Chemotherapy, Adjuvant; Coronary Angiography; Feasib | 1998 |
[Thromboembolism prevention in acute myocardial infarction].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Coronary Care Units; Cross-Sectional St | 2001 |
The in vitro effect of a low molecular weight heparin, nadroparin (Fraxiparine), on leukocytes obtained from patients with vascular diseases.
Topics: Aged; Anticoagulants; Aortic Aneurysm, Abdominal; Dose-Response Relationship, Drug; Humans; Leukocyt | 2001 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Comorbidity; E | 2021 |
Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?
Topics: Aged; Aminopyridines; Antineoplastic Agents; Artifacts; Benzimidazoles; Breast Neoplasms; Coronary V | 2021 |
Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Coronary Thrombosis; Drug Administ | 2017 |
Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention.
Topics: Aged; Anticoagulants; Coronary Artery Disease; Enoxaparin; Female; Heparin; Humans; Male; Middle Age | 2018 |
Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients.
Topics: Benzamides; Enoxaparin; Female; Humans; Male; Myocardial Infarction; Pyridines; Risk Factors; Stroke | 2019 |
Prognostic significance of bleeding location and severity among patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Blood Loss, Surgical; Coronary Artery Bypass; Enoxapa | 2013 |
Spontaneous triple coronary artery dissection in a 78-year-old woman resolved angiographically with anticoagulation and medical management.
Topics: Aged; Anticoagulants; Aortic Dissection; Coronary Aneurysm; Coronary Angiography; Enoxaparin; Female | 2013 |
Giant thrombus on apical wall of left ventricle due to HIT syndrome after anterior MI.
Topics: Anticoagulants; Enoxaparin; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Infarction; Thro | 2014 |
Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
Topics: Aged; Angina, Unstable; Anticoagulants; Cohort Studies; Drug Monitoring; Enoxaparin; Factor Xa; Fact | 2013 |
A case of neonatal myocardial infarction: left coronary artery thrombus resolution and normalisation of ventricular function by intracoronary low-dose tissue plasminogen activator.
Topics: Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Vessel Anomalies; Coronary V | 2015 |
Cardioembolic acute myocardial infarction associated with apical ballooning: Considerations.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Echocardiog | 2015 |
Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy.
Topics: Aged; Anticoagulants; Clopidogrel; Drug Therapy, Combination; Enoxaparin; Europe; Female; Fibrinolyt | 2015 |
Individualized dosing of enoxaparin in a morbidly obese patient by monitoring the anti-factor Xa.
Topics: Blood Coagulation; Blood Coagulation Tests; Body Mass Index; Drug Dosage Calculations; Drug Monitori | 2017 |
2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice.
Topics: Angioplasty, Balloon, Coronary; Cardiology; Clopidogrel; Emergency Service, Hospital; Enoxaparin; Ev | 2008 |
2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies.
Topics: American Heart Association; Angina, Unstable; Anticoagulants; Clopidogrel; Drug-Eluting Stents; Enox | 2008 |
Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Enoxaparin; Female; Fibrinolytic Agen | 2008 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R | 2008 |
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Combined Modality Therapy; C | 2009 |
Spotlight on enoxaparin in ST-segment elevation myocardial infarction.
Topics: Anticoagulants; Electrocardiography; Enoxaparin; Humans; Myocardial Infarction | 2008 |
ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy.
Topics: Aged; Anticoagulants; Clopidogrel; Combined Modality Therapy; Comorbidity; Disease-Free Survival; Dr | 2009 |
Acute myocardial infarction in pregnancy.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Apgar Score; Aspirin; Cesarean Section; Coron | 2008 |
Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Drug Therapy, Combination; Enoxaparin; Fibr | 2009 |
Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
Topics: Acute Coronary Syndrome; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fond | 2009 |
Low-molecular-weight heparin as an adjunct to thrombolysis in ST elevation myocardial infarction.
Topics: Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Routes; Electrocardiogra | 2009 |
Antithrombin therapy for elective percutaneous coronary intervention: which agent to use? Does it matter?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin | 2009 |
Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice.
Topics: Cost-Benefit Analysis; Decision Trees; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heparin | 2010 |
Enoxaparin and fibrinolysis: ExTRACTing prognosis from bleeding complications.
Topics: Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Myocardial Infarction | 2010 |
Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Chi-Square Distribution; | 2011 |
Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Drug-Eluting Stents; Enoxaparin; Heparin; Hospital M | 2010 |
Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; Drug-Eluting Stents; Enox | 2010 |
Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids.
Topics: Adult; Anabolic Agents; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopid | 2010 |
Unfractionated versus low-molecular-weight heparin for primary angioplasty-More data suggesting to go low.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Evidence-Based Medicine; Hemorrhage; Hep | 2011 |
Total occlusion of aortic arch in a 62-year-old man presenting with acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aorta, Thoracic; Aortic Diseases; Clopidogrel; Coronary Angiography; | 2011 |
Antithrombin alternatives in STEMI.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Electrocardiography; Enoxaparin; Fibrinolytic Agents | 2011 |
An unusual case of massive subcutaneous chest wall haemorrhage with enoxaparin.
Topics: Aged; Anticoagulants; Diagnosis, Differential; Enoxaparin; Hemorrhage; Humans; Injections, Subcutane | 2011 |
Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents.
Topics: Anticoagulants; Drug-Eluting Stents; Electrocardiography; Enoxaparin; Female; Heparin; Humans; Male; | 2012 |
Enoxaparin for anticoagulation in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Heparin; Humans | 2012 |
Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxap | 2012 |
Abciximab for distal thromboaspiration catheter-related embolization in ST-segment elevated myocardial infarction.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary Angi | 2012 |
Acute myocardial infarction and heart block: a challenge to emergency physicians.
Topics: Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heart Block; Humans; Mal | 2013 |
Safety of subcutaneous enoxaparin as ancillary therapy in STEMI patients receiving fibrinolysis.
Topics: Adult; Enoxaparin; Female; Fibrinolysis; Fibrinolytic Agents; Humans; Injections, Subcutaneous; Male | 2013 |
Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; China; Combined Modality Therapy; Coronary Art | 2002 |
Further evidence that antithrombotic therapy is beneficial with streptokinase: improved early ST resolution and late patency with enoxaparin.
Topics: Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Humans; Myocardial Infarction; Streptoki | 2002 |
Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Computer Simulation; Enoxaparin; Humans; Models | 2002 |
Evidence-based risk stratification to target therapies in acute coronary syndromes.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Biomarkers; Cardiac Catheterization; Clopidogrel; Co | 2002 |
Enoxaparin after high-risk coronary stenting.
Topics: Anticoagulants; Blood Vessel Prosthesis Implantation; Enoxaparin; Humans; Myocardial Infarction; Pos | 2002 |
Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports.
Topics: Acute Disease; Aged; Angina, Unstable; Blood Component Transfusion; Coronary Artery Bypass; Coronary | 2002 |
Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Enoxap | 2002 |
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno | 2003 |
The use of putative placebo in active control trials: two applications in a regulatory setting.
Topics: Angina, Unstable; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as | 2003 |
Safety and efficacy of low-dose intravenous enoxaparin and GP IIb/IIIa inhibitor therapy during PCI.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; Dose-Response Relat | 2003 |
The search for optimal combination of antiplatelet and anticoagulation regimens following PCI.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; Enoxaparin; Humans; Myoca | 2003 |
[The safety and efficacy of pre-treatment with enoxaparin (Clexane) in acute coronary syndrome patients undergoing percutaneous coronary intervention].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; E | 2003 |
Primary PCI for ST-segment elevation myocardial infarction in a patient treated with subcutaneous enoxaparin utilizing point-of-care Enox test.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Elect | 2003 |
Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
Topics: Aged; Anticoagulants; Coronary Disease; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Ki | 2003 |
Myocardial infarction and ischemia.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Endothelial Growth Factors; Enoxaparin; Humans; Inte | 2003 |
Confusion in reperfusion.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Elective Surgical | 2003 |
Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study.
Topics: Adolescent; Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Enoxaparin; | 2004 |
Seamless anticoagulation therapy utilizing enoxaparin for acute coronary syndromes: Measure or not, here it comes!
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Drug Administration Schedule; | 2004 |
Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation.
Topics: Anticoagulants; Blood Cell Count; Coronary Angiography; Drug Therapy, Combination; Enoxaparin; Eptif | 2004 |
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
Topics: Analysis of Variance; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Cath | 2004 |
Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Comorbidity; Drug | 2004 |
Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Coronary Disease; E | 2004 |
Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials, Phase II as Topic; Cohort Studies; Coronary Angi | 2004 |
Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey.
Topics: Canada; Emergency Medical Services; Enoxaparin; Europe; Fibrinolytic Agents; Health Care Surveys; He | 2004 |
[Enoxaparin for the Treatment of Unstable Angina and Non-ST Segment Elevation Myocardial Infarction: the ENO-INT Study].
Topics: Angina, Unstable; Anticoagulants; Enoxaparin; Heparin; Humans; Myocardial Infarction | 2004 |
Fractionating heparins and their clinical trial data--something for everyone.
Topics: Angina Pectoris; Angina, Unstable; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infa | 2004 |
Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes?
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Dose-Response Relationsh | 2004 |
Allergic reactions to enoxaparin and heparin: a case report and review of the literature.
Topics: Aged; Anaphylaxis; Anticoagulants; Drug Eruptions; Enoxaparin; Female; Heparin; Humans; Myocardial I | 2004 |
Enoxaparin vs unfractionated heparin in acute coronary syndrome.
Topics: Angina Pectoris; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction | 2004 |
Enoxaparin vs unfractionated heparin in acute coronary syndrome.
Topics: Angina Pectoris; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction | 2004 |
Prehospital thrombolysis perfomed by a ship's nurse with on-line physician consultation.
Topics: Aged; Emergency Medical Services; Emergency Nursing; Enoxaparin; Female; Fibrinolytic Agents; Humans | 2005 |
Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Bayes Theorem; Enoxaparin; Health Care Costs; Hep | 2005 |
Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thro
Topics: Double-Blind Method; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Multicen | 2005 |
On "Current role of antithrombotic agents in the treatment of acute coronary syndromes" (Semin Thromb Hemost 2004;30:627-632).
Topics: Cerebral Hemorrhage; Confounding Factors, Epidemiologic; Enoxaparin; Fibrinolytic Agents; Hemorrhage | 2005 |
Enoxaparin and percutaneous coronary intervention: a Canadian perspective.
Topics: Angina, Unstable; Angioplasty, Balloon; Anticoagulants; Attitude of Health Personnel; Canada; Dose-R | 2005 |
Dose capping enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Biological Availability; Clinical Trials as Topic; | 2005 |
Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Dose-Response Relationship, Drug; Enoxaparin; Fact | 2005 |
Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiac Catheterization; Co | 2005 |
The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibito
Topics: Anticoagulants; Coronary Disease; Drug Interactions; Endothelium, Vascular; Enoxaparin; Fibrinolytic | 2005 |
A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data.
Topics: Anticoagulants; Coronary Artery Bypass; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Meta-Anal | 2005 |
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Female; Hemorrhage; Heparin; Hum | 2005 |
Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial.
Topics: Acute Disease; Anticoagulants; Arrhythmias, Cardiac; Enoxaparin; Eptifibatide; Heparin; Humans; Myoc | 2005 |
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
Topics: Aged; Anticoagulants; Coronary Disease; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middl | 2005 |
Abciximab in the treatment of ST-segment elevation myocardial infarction.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Enoxaparin; Fibrinolytic Agents; | 2005 |
Acute myocardial infarction in a young woman with antiphospholipid syndrome and occasional cocaine abuse.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Cocaine-Related Disorders; Coronary | 2005 |
Prehospital administration of enoxaparin before primary angioplasty for ST-elevation acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Emergency Medical Services; En | 2006 |
Eczema-like plaques secondary to enoxaparin.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anticoagulants; Diagnosi | 2006 |
Blood thinner cuts risk of bleeding in half.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Myocardial Infarction; Polysaccharides | 2006 |
Therapy for patients with acute coronary syndromes--new opportunities.
Topics: Angina, Unstable; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Fondaparinux; Hemorr | 2006 |
The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
Topics: Angina, Unstable; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Mal | 2006 |
The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibito
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Drug Administration Schedule; Drug Therapy, Combinat | 2006 |
The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Enoxaparin; Female; Fibrin; Fibrin F | 2007 |
Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.
Topics: Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; | 2006 |
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2006 |
[Prophylaxis of venous thromboembolism in acutely ill medical patients].
Topics: Acute Disease; Aged; Dalteparin; Enoxaparin; Fibrinolytic Agents; Health Status; Humans; Middle Aged | 2006 |
Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
Topics: Aged; Anticoagulants; Coronary Disease; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Myoca | 2006 |
Fondaparinux versus enoxaparin in acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Bypass; Drug Thera | 2006 |
Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial In | 2006 |
Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial Infarction | 2006 |
Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clinical Trials, Phase III as Topic; Drug Therapy, C | 2006 |
Clinical trials update from the annual scientific session of the American College of Cardiology 2006.
Topics: Aspirin; Cardiac Catheterization; Cardiology; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2006 |
Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Enox | 2007 |
[The best of thrombosis in 2006].
Topics: Anticoagulants; Cardiology; Clinical Trials as Topic; Coronary Disease; Enoxaparin; Humans; Myocardi | 2007 |
Acute myocardial infarction complicated by ventricular standstill terminated by thrombolysis and transcutaneous pacing.
Topics: Adult; Cardiac Pacing, Artificial; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Femal | 2007 |
Effects of the early administration of heparin in patients with ST-elevation myocardial infarction treated by primary angioplasty.
Topics: Angioplasty, Balloon; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Myocar | 2007 |
Substitution of fractionated for unfractionated heparin during high-risk percutaneous coronary intervention: has the problem been solved?
Topics: Angioplasty, Balloon, Coronary; Chemotherapy, Adjuvant; Enoxaparin; Fibrinolytic Agents; Heparin; Hu | 2007 |
Bleeding during enoxaparin treatment more common with age over 75 years and severe renal insufficiency.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Endpoint Determination; Enoxapa | 2007 |
The Editor's Roundtable: arterial thrombosis and acute coronary syndromes.
Topics: Administration, Cutaneous; Angina, Unstable; Anticoagulants; Cardiac Catheterization; Comorbidity; C | 2007 |
Enoxaparin and ST elevation myocardial infarction.
Topics: Aspirin; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Inf | 2007 |
TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cause of Death; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Hepa | 2007 |
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Topics: Acute Coronary Syndrome; Aged; Blood Transfusion; Coronary Angiography; Enoxaparin; Female; Fibrinol | 2007 |
[The safety of enoxaparine use in elderly with acute myocardial infarction].
Topics: Age Factors; Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Myocardial | 2007 |
Evaluating the optimal timing of angiography: landmark or off the mark?
Topics: Acute Coronary Syndrome; Aged; Blood Transfusion; Coronary Angiography; Enoxaparin; Female; Fibrinol | 2007 |
Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Germany; Hemorrhage; Hepar | 2008 |
[Acute myocardial infarction in pregnancy of 39 week treated with fibrinolysis].
Topics: Adult; Cardiac Catheterization; Enoxaparin; Female; Fibrinolytic Agents; Humans; Infant, Newborn; My | 2008 |
[Stents, antiplatelet therapy, and surgery].
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cesarean Section; Enoxaparin; Female | 2008 |
Heparin-induced thrombocytopenia and paradoxical venous thromboses.
Topics: Aged; Axillary Vein; Coronary Disease; Diabetes Mellitus, Type 2; Enoxaparin; Female; Femoral Vein; | 1993 |
Heparin in acute coronary disease--requiem for a heavyweight?
Topics: Angina, Unstable; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction | 1997 |
News from the FDA Cardio-renal Advisory Committee meeting of June 26, 1997.
Topics: Antihypertensive Agents; Drug Approval; Enoxaparin; Fenoldopam; Half-Life; Humans; Myocardial Infarc | 1997 |
Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
Topics: Abciximab; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 1999 |
Pursuing progress in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Enoxapa | 1999 |
Improving outcome in acute coronary syndromes - as good as it gets?
Topics: Angina, Unstable; Anticoagulants; Dalteparin; Enoxaparin; Humans; Myocardial Infarction; Platelet Gl | 1999 |
Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Enoxaparin; Humans; Myocardial Infarction; Tr | 1999 |
Care for life. Central is the patient.
Topics: Angina, Unstable; Anticoagulants; Awards and Prizes; Death, Sudden, Cardiac; Enoxaparin; Germany; Hu | 2000 |
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Topics: Angina, Unstable; Blood Platelets; Enoxaparin; Factor Xa; Heparin, Low-Molecular-Weight; Humans; Myo | 2000 |
Use of enoxaparin in a patient with unstable angina.
Topics: Angina, Unstable; Blood Chemical Analysis; Cardiac Catheterization; Coronary Angiography; Coronary A | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Topics: Angina, Unstable; Angioplasty; Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials as | 2000 |
Management of unstable angina and myocardial infarction.
Topics: Angina, Unstable; Enoxaparin; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; M | 2000 |
Concomitant use of eptifibatide and enoxaparin in the medical management of a patient with a non-ST segment elevation acute coronary syndrome and in-stent restenosis.
Topics: Adult; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Drug Therapy, Combina | 2000 |
A simple, readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction.
Topics: Aged; Angina, Unstable; Anticoagulants; Chi-Square Distribution; Enoxaparin; Female; Heparin; Humans | 2001 |
Cost prediction models for the comparison of two groups.
Topics: Angina, Unstable; Anticoagulants; Cost-Benefit Analysis; Drug Costs; Enoxaparin; Hospital Costs; Hum | 2001 |
Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Topics: Angina Pectoris; Anticoagulants; Blood Coagulation; Cardiac Catheterization; Dose-Response Relations | 2001 |
[Cutaneous hypersensitivity reaction to enoxaparin].
Topics: Aged; Drug Eruptions; Enoxaparin; Female; Fibrinolytic Agents; Humans; Myocardial Infarction | 2001 |
New thrombolytic regimens in acute myocardial infarction.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Huma | 2001 |
Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non--ST- segment elevation acute myocardial infarction.
Topics: Aged; Angina, Unstable; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2002 |
Enoxaparin in ST elevation MI - a bright future.
Topics: Anticoagulants; Enoxaparin; Forecasting; Heparin; Humans; Myocardial Infarction; Treatment Outcome | 2002 |
Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes.
Topics: Acute Disease; Aged; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Disease | 2002 |
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
Topics: Age Factors; Aged; Angina, Unstable; Area Under Curve; Aspirin; Biomarkers; Body Weight; Coronary Ar | 2002 |
Tenecteplase: new preparation. Another thrombolytic agent for myocardial infarction: a slightly simpler treatment.
Topics: Age Factors; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial | 2002 |
Simple principles of clinical trials remain powerful.
Topics: Anticoagulants; Cardioplegic Solutions; Clinical Trials as Topic; Glucose; Heparin, Low-Molecular-We | 2005 |
Reviparin in acute myocardial infarction.
Topics: Anticoagulants; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; R | 2005 |
Reviparin in acute myocardial infarction.
Topics: Anticoagulants; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; R | 2005 |
Dalteparin-associated catastrophic retroperitoneal hematoma successfully treated with recombinant factor VIIa.
Topics: Aged; Anticoagulants; Dalteparin; Factor VIIa; Hematoma; Humans; Male; Myocardial Infarction; Recomb | 2012 |
The RITA 3 trial.
Topics: Aged; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Dalteparin; Humans; Myocardial Inf | 2002 |
Dalteparin sodium (fragmin) administration following acute infarction does not affect myocardial perfusion and function in swine.
Topics: Animals; Anticoagulants; Coronary Circulation; Dalteparin; Female; Fibroblast Growth Factors; Inject | 2002 |
Depo-heparin for long term therapy of myocardial infarction.
Topics: Cardiovascular Diseases; Dalteparin; Heparin; Humans; Myocardial Infarction | 1952 |
Depo-heparin therapy in management of acute myocardial infarction.
Topics: Anterior Wall Myocardial Infarction; Anticoagulants; Dalteparin; Heparin; Humans; Myocardial Infarct | 1955 |
ST-segment analyses and residual thrombi in the infarct-related artery: a report from the ASSENT PLUS ST-monitoring substudy.
Topics: Aged; Coronary Angiography; Coronary Thrombosis; Dalteparin; Electrocardiography; Female; Fibrinolyt | 2004 |
Comparison of abciximab combined with dalteparin or unfractionated heparin in high-risk percutaneous coronary intervention in acute myocardial infarction patients.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Blood Loss, Surgi | 2006 |
Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction.
Topics: Animals; Anticoagulants; Collagen; Dalteparin; Factor XIII; Fibrinolytic Agents; Heart Rupture, Post | 2008 |
The effect of low molecular weight heparin (fragmin) on myocardial neutrophil accumulation and infarct size in a rat model of myocardial infarction.
Topics: Animals; Anticoagulants; Dalteparin; Disease Models, Animal; Heart; Lymphocyte Activation; Male; Myo | 1996 |
Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease.
Topics: Angina, Unstable; Antibodies, Anti-Idiotypic; Anticoagulants; Biomarkers; C-Reactive Protein; Chlamy | 1998 |
New trials of LMW heparins - light and heavy weight as good on short but what about longer distances?
Topics: Angina, Unstable; Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Myocardial Infa | 1999 |
[Dalteparin in the acute phase of unstable angina and non-Q-wave infarction].
Topics: Acute Disease; Angina, Unstable; Dalteparin; Fibrinolytic Agents; Humans; Myocardial Infarction | 2000 |
Dalteparin for unstable angina and non-Q-wave myocardial infarction.
Topics: Angina, Unstable; Dalteparin; Electrocardiography; Fibrinolytic Agents; Humans; Myocardial Infarctio | 2000 |
Acute coronary syndromes: extending medical intervention for five days before proceeding to revascularization.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Art | 2000 |
Evaluating the place of low-molecular-weight heparin in the management of acute coronary syndromes. A panel discussion with audience participation.
Topics: Angina, Unstable; Anticoagulants; Atrial Fibrillation; Dalteparin; Heparin, Low-Molecular-Weight; Hu | 2001 |